US Pat. No. 10,188,795

BLOOD GLUCOSE CONTROL SYSTEM

Trustees of Boston Univer...

1. A sensor-driven glucose control system, comprising:an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller operative to generate the insulin dose control signal by:
(1) continually administering priming doses of insulin at respective times, each priming dose being of a respective amount and having a prescribed interval of action;
(2) receiving information regarding total amounts of insulin administered during the prescribed intervals of action, each total amount including an aggregation of total doses administered in response to a glucose level signal; and
(3) automatically adapting the amounts of the priming doses in response to a mathematical relationship, over respective periods each spanning multiple prescribed intervals of action, between the amounts of the priming doses and the total amounts of insulin administered during the prescribed intervals of action.

US Pat. No. 10,188,788

SYSTEM AND METHODS FOR MEDICAMENT INFUSION

Medirio S.A., Visp (CH)

1. A system for trans-dermal delivery of a dose of a medicament, comprising a delivery device and a separate hand-held drive device, whereinthe delivery device is configured to be placed in dermal contact with a patient, the delivery device comprising
a reservoir for holding the medicament to be delivered,
a trans-dermal injection element for delivering the dose of the medicament to the patient,
a control unit for controlling the transformation of external energy transferred from the hand-held drive device to the delivery device into a pumping force and for allowing a specific dose of the medicament to be pumped when the dose is requested, the control unit comprising
one or more rotors and/or one or more axial pump elements for transforming rotational and/or axial force into the pumping force, and
at least one safe-lock mechanism for preventing mechanical action to cause rotation of the at least one or more rotors and/or movement of the one or more axial pump elements thereby preventing passage of the medicament from the reservoir to the trans-dermal injection element unless a dose is requested;
the separate hand-held drive device being configured to be placed temporarily in proximity to the delivery device when a dose of medicament is required, the hand-held drive device comprising an activation unit for activating the control unit of the delivery device, the activation unit comprising
at least one unlocking element to provide energy to the control unit of the delivery device for unlocking the at least one safe-lock mechanism and a drive unit to provide energy for any of the one or more rotors and/or one or more axial pump elements of the control unit, only when the separate hand-held drive device is in proximity to the delivery device, and
wherein the hand-held drive device comprises a sensor capable of detecting the amount of energy being transferred and/or transformed into pumping force.

US Pat. No. 10,188,784

APPARATUS WITH RIGID MEMBER FOR SENSING FLUID PRESSURE

FENWAL, INC., Lake Zuric...

1. A blood processing system, comprising:a first housing configured to be reused for multiple blood processing operations for different donors;
a second housing configured for a single blood processing operation, the second housing insertable to and removable from the first housing, the second housing comprising a conduit configured to house blood and a pressure sensing portion having a rigid member disposed thereon, the rigid member configured to move in response to a change in pressure of the blood; and
a sensor system coupled to the first housing and configured to be reused for multiple blood processing operations, the sensor system comprising a second member and a sensor, the second member removeably coupled to the rigid member, the sensor configured to detect across an air gap movement of the second member and to generate a signal indicative of the movement.

US Pat. No. 10,188,779

IMPLANTABLE PUMP SYSTEM HAVING AN UNDULATING MEMBRANE WITH IMPROVED HYDRAULIC PERFORMANCE

CorWave SA, Clichy (FR)

1. An implantable blood pump system comprising:a housing having an inlet and an outlet and configured to be implanted at a patient's heart;
a membrane disposed within the housing;
a skirt disposed within the housing and coupled to the membrane, the skirt sized and shaped to extend toward the inlet and to curve toward the outlet; and
an actuator disposed within the housing, the actuator configured to cause the membrane to reciprocate and deform in a wave-like manner,
wherein during operation blood enters the inlet, flows toward the skirt which guides the blood towards the membrane, and is propelled across the membrane to the outlet.

US Pat. No. 10,188,767

SCENT PRESENTATION METHOD, SCENT PRESENTATION APPARATUS, AND OLFACTION IMPROVING APPARATUS

KEIO UNIVERSITY, Tokyo (...

1. An olfaction improvement method comprising:determining a detection threshold at which a test subject is able to detect a scent selected from among a plurality of scents by
presenting the scent by pulse ejecting the scent for a specified time interval between from about 100 ms to about 300 ms to vary the intensity of the scent,
detecting an operation of a terminal device by the test subject upon detection of the scent by the test subject, and
setting the intensity of the scent detected by the test subject over at least two consecutive trials as the detection threshold of the test subject for each scent from among the plurality of scents, wherein the plurality of scents are selected and presented in a predetermined sequence;
generating a random number to randomly determine a presentation sequence of the plurality of scents;
determining presentation conditions that include the intensity of the scent and the pulse ejection duration of the scent based on the detection threshold of the test subject;
presenting the scent through pulse ejection based on the determined presentation condition; and
altering the presentation conditions by reducing the intensity of the scent, the pulse ejection duration of the scent, or both the intensity of the scent and the pulse ejection duration of the scent relative to the detection threshold of the test subject when presenting the scent at a subsequent time, wherein
the scent is pulse ejected by a fluid ejection device.

US Pat. No. 10,188,766

PURIFIED HYDROGEN PEROXIDE GAS MICROBIAL CONTROL METHODS AND DEVICES

Synexis LLC, Kansas City...

1. A diffuser apparatus for producing non-hydrated purified hydrogen peroxide gas (PHPG) from humid ambient air-comprising:(a) an air distribution mechanism providing an airflow of said humid ambient air;
(b) a source of ultraviolet light; and
(c) a metal, or metal oxide catalyst on a thin, air-permeable substrate structure having a surface,
wherein said air flow is through; said surface and has a residence time on said air-permeable substrate structure of less than a second, wherein said non-hydrated purified hydrogen peroxide gas comprises 0.015 ppm of ozone or less and is directed out of said diffuser apparatus and into an environment when said apparatus is in operation.

US Pat. No. 10,188,763

APPARATUS AND METHOD FOR SANITIZING STETHOSCOPE HEADS

1. A method for santizing a stethoscope head having a diaphragm and a bell, the method comprising:providing an apparatus configured to apply a sanitizing fluid to the stethescope head, the apparatus comprising:
a housing shaped to retain a sanitizing fluid; and
an applicator pad connected to the housing and in selective fluid communication with the sanitizing fluid, the applicator pad comprising a raised portion having a substantially hemi-spherical shape configured to at least partially extend into an interior region of the bell of the stethoscope head when the bell is placed against the raised portion;
dispensing the santizing fluid from the housing and unto the applicator pad, the applicator pad formed from a porous, absorbent material that absorbs the sanitizing fluid when the sanitizing fluid dispenses out of the housing and onto the applicator pad; and
applying the sanitizing fluid to the bell of the stethoscope head by placing the interior region of the bell against the raised portion of the applicator pad.

US Pat. No. 10,188,754

COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MAGNETIC RESONANCE IMAGING (MRI)

The Johns Hopkins Univers...

1. A method of producing a magnetic resonance (MR) image of a target, comprising:introducing a magnetic resonance imaging (MRI) contrast agent to the target; and
imaging the target using a Chemical Exchange Saturation Transfer (CEST) or frequency labeled exchange (FLEX) based MRI technique to produce the MR image of the target,
wherein the MRI contrast agent is a compound of Formula (I), or a salt or stereoisomer thereof:
wherein:R1 and R2 are each independently H, SR, phosphorus, alkyl, amino, alkoxyl, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)-alkyl, or —C(O)O-alkyl; or R1, and R2, taken together with the bonds they are attached to, form an aryl or heteroaryl group; wherein said amino, alkyl, alkoxyl, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)-alkyl, or —C(O)O-alkyl moiety is optionally substituted;
when Y is O, R3 is H, and when Y is NR5, R3 is selected from the group consisting of H, phosphorus, alkyl, —S(O)2R, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)-alkyl, or —C(O)O-alkyl, wherein said alkyl, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)-alkyl, or —C(O)O-alkyl moiety is optionally substituted, provided that at least one of R3 and R5 is H;
R4 is H, phosphorus, halogen, SR, hydroxyl, amino, alkoxyl, alkyl, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)-alkyl, or —C(O)O-alkyl, wherein said alkyl, amino, alkoxyl, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)-alkyl, —C(O)O-alkyl moiety is optionally substituted; and
X is O, NR5, alkyl, or S;
Y is O or NR5; and
wherein each R5 is independently selected from the group consisting of H, alkyl, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)— alkyl, or —C(O)O-alkyl, wherein said alkyl, cycloalkyl, arylalkyl, cycloalkyl-alkyl, heterocyclic, heteroaryl-alkyl, aryl, heteroaryl, —C(O)-alkyl, or —C(O)O-alkyl moiety is optionally substituted.

US Pat. No. 10,188,746

PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF

MEDIMMUNE LIMITED, Cambr...

1. A conjugate of formula (A):
and salts and solvates thereof, wherein:
D represents either group D1 or D2:

the dotted line indicates the optional presence of a double bond between C2 and C3;
when there is a double bond present between C2 and C3, R2 is selected from the group consisting of:
(ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene;
(ib) C1-5 saturated aliphatic alkyl;
(ic) C3-6 saturated cycloalkyl;
(id)
wherein each of R31, R32 and R33 are independently selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R2 group is no more than 5;(ie)
wherein one of R35a and R35b is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and(if)
where R34 is selected from: H; C1-3 saturated alkyl; C2-3 alkenyl; C2-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;(ig) halo;
when there is a single bond present between C2 and C3,
R2 is
where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R16a and R16b is H, the other is selected from nitrile and a C1-4 alkyl ester;R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, SnMe3 and halo;
either
(a) R10 is H, and R11 is OH or ORA, where RA is C1-4 alkyl; or
(b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or
(c) R10 is H and R11 is OSOZM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; or
(d) R11 is OH or ORA, where RA is C1-4 alkyl and R10 is selected from:
where Rz is selected from:(z-i)

(z-ii) OC(?O)CH3;
(z-iii) NO2;
(z-iv) OMe;
(z-v) glucoronide;
(z-vi) —C(?O)—X1—NHC(?O)X2—NH—RZC, where —C(?O)—X1—NH— and —C(?O)—X2—NH— represent natural amino acid residues and Rzc is selected from Me, OMe, OCH2CH2OMe;
Y is selected from formulae A1 and A2:

Z1 is a C1-3 alkylene group;
Z2 is a C1-3 alkylene group;
Q is:
where QX is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue;L is a linker connected to a cell binding agent;
CBA is the cell binding agent;
n is an integer between 0 and 48;
R and R? are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR?, R and R? together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
R8 is either:
(a) independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, SnMe3 and halo; or
(b) of formula A*:
wherein:D? represents either group D?1 or D2:

wherein the dotted line indicates the optional presence of a double bond between C2? and C3?;
R17 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, SnMe3 and halo;
R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted; and
X and X? are independently selected from O, S and N(H); and
R22, R16, R19, R20 and R21 are as defined for R2, R6, R9, R10 and R11 respectively.

US Pat. No. 10,188,743

CYTISINE-LINKED ISOFLAVONOID ANTINEOPLASTIC AGENTS FOR THE TREATMENT OF CANCER

University of Kentucky Re...

1. A method of treating prostate or colorectal cancer, the method comprising administering to a patient in need of prostate or colorectal cancer treatment an effective amount of a cytisine-linked isoflavonoid compound represented by formula (I):
or pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof,
wherein Ar is an aryl or heteroaryl; n is an integer from 1 to 5; each X is independently a halide, or alkoxy, or more than one X on Ar together form a cyclic ether structure; and wherein the compound is substituted on the C-2 position with H, alkyl, cycloalkyl or alkoxy, substituted on the C-5, C-6, C-7, and C-8 positions independently with H, hydroxy (OH), alkyl, cycloalkyl, alkoxy, L is a substituted or unsubstituted di-radical linker group that links the cytisinyl group to either the C-5, C-6, C-7 or C-8 position.

US Pat. No. 10,188,690

USE OF KAEMPFERIA PARVIFLORA WALL. EX. BAKER EXTRACTS OR FLAVONE COMPOUND FOR PREVENTING OR TREATING MUSCLE DISEASES, OR IMPROVING MUSCLE FUNCTION

AAT COSTECH CO., LTD., S...

1. A method of treating a human suffering from muscle atrophy comprising administering to said human suffering from muscle atrophy a therapeutically effective amount of a compound represented by Formula 4 or salt thereof to the human suffering from muscle atrophy,wherein Formula 4 is as follows:

wherein each of R1, R2, and R3 is independently selected from the group consisting of hydrogen and methoxy, and
wherein the human has a muscle disease selected from the group consisting of atony, muscular dystrophy, myasthenia, and sarcopenia.

US Pat. No. 10,188,642

PHARMACOLOGICALLY ACTIVE COMPOUNDS

Cancer Research Technolog...

1. A compound having the structural formula II shown below:
wherein:
X is CH or N;
Y is N or C—H;
R2 is (1-6C)alkyl, (1-8C)heteroalkyl, aryl, aryl(1-2C)alkyl, a 5 or 6 membered heteroaryl, a 5 or 6 membered heteroaryl(1-2C)alkyl, a 3 to 6 membered heterocyclyl, a 3 to 6 membered heterocyclyl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, C(O)R13, C(O)OR13, OC(O)R13, C(O)N(R14)R13, S(O)xR13 (where x is 0, 1 or 2), or SO2N(R14)R13;
and wherein R2 is optionally substituted by one or more substituent groups selected from fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, S(O)xCH3 (where x is 0, 1 or 2), methylamino or dimethylamino, aryl, aryl(1-2C)alkyl, heteroaryl, heteroaryl(1-2C)alkyl, heterocyclyl, heterocyclyl(1-2C)alkyl, (3-8C)cycloalkyl, and (3-8C)cycloalkyl(1-2C)alkyl,
and wherein any (1-4C)alkyl, (1-4C)alkoxy, aryl, heteroaryl, heterocyclyl, or (3-8C)cycloalkyl moiety present within a substituent group on R2 is optionally further substituted by fluoro, chloro, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, (1-4C)alkyl, NRcRd, ORc, C(O)Rc, C(O)ORc, OC(O)Rc, N(Rd)ORc, C(O)N(Rd)Rc, N(Rd)C(O)Rc, S(O)yRc (where y is 0, 1 or 2), SO2N(Rd)Rc, or N(Rd)SO2Rc, wherein Rc and Rd are each independently H or (1-4C)alkyl;
R3 is hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, halo, CF3, CN or (1-4C)alkoxy;
R4 is hydrogen, fluoro, chloro or CF3;
Ar has the formula:

wherein:
(i) all of A1, A2 and A3 are CH; or
(ii) A3 is CH and A1 or A2 are N or CH;
R5 is cyano, (1-3C)alkyl, (1-3C)fluoroalkyl, (1-3C)alkoxy, (1-3C)fluoroalkoxy, halo, (1-3C)alkanoyl, C(O)NR15R16 or S(O)2NR15R16, and wherein R15 and R16 are each independently H or (1-3C)alkyl, and wherein any alkyl or alkoxy moities present within a R5 substituent group are optionally further substituted by hydroxy or methoxy;
R6 is halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, ureido, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl,
or R6 is a group of the formula:
-L1-L2-R17
wherein
L1 is absent or a linker group of the formula —[CR18R19]n— in which n is an integer selected from 1, 2, 3 and 4, and R18 and R19 are each independently hydrogen or (1-2C)alkyl;
L2 is absent or is O, S, SO, SO2, N(R20), C(O), C(O)O, OC(O), CH(OR20), C(O)N(R20), N(R20)C(O), N(R20)C(O)N(R21), S(O)2N(R20), or N(R21)SO2, wherein R20 and R21 are each independently selected from hydrogen or (1-2C)alkyl; and
R17 is (1-6C)alkyl, aryl, aryl-(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-4C)alkyl, heteroaryl, heteroaryl-(1-4C)alkyl, heterocyclyl, or heterocyclyl-(1-4C)alkyl,
 and wherein R17 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, NR22R23, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-5C)alkanoyl, (1-5C)alkylsulphonyl, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, CONR22R23, and SO2NR22R23; wherein R22 and R23 are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or R22 and R23 can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring ring;
 and wherein when said substituent group comprises an alkyl, cycloalkyl, heterocyclyl or heteroaryl moiety then said moiety is optionally further substituted by hydroxy, fluoro, chloro, cyano, CF3, OCF3, (1-2C)alkyl, (1-2C)alkoxy, SO2(1-2C)alkyl or NReRf (where Re and Rf are each independently hydrogen, (1-3C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl);
or R17 is a group having the formula:
-L3-L4-R24
wherein
L3 is absent or a linker group of the formula —[CR25R26]n— in which n is an integer selected from 1, 2, 3 or 4, and R25 and R26 are each independently hydrogen or (1-2C)alkyl;
L4 is absent or is O, S, SO, SO2, N(R27), C(O), C(O)O, OC(O), CH(OR27), C(O)N(R27), N(R27)C(O), N(R27)C(O)N(R28), S(O)2N(R27), or N(R28)SO2, wherein R27 and R28 are each independently hydrogen or (1-2C)alkyl; and
R24 is (1-6C)alkyl, aryl, aryl-(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-4C)alkyl, heteroaryl, heteroaryl-(1-4C)alkyl, heterocyclyl, or heterocyclyl-(1-4C)alkyl;
R13 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, or heteroaryl-(1-2C)alkyl, and wherein R13 is optionally further substituted by one or more substituents selected from hydroxy, fluoro, chloro, cyano, CF3, OCF3 (1-2C)alkyl and (1-2C)alkoxy;
R14 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl-(1-2C)alkyl, and wherein R14 is optionally further substituted by one or more substituents selected from hydroxy, fluoro, chloro, cyano, CF3, OCF3, (1-2C)alkyl and (1-2C)alkoxy;
subject to the proviso that:
X can only be N when Y is N;
when X and Y are both N, R3 is H or fluoro;
or a pharmaceutically acceptable salt or solvate thereof.

US Pat. No. 10,188,588

ACIDIC HYBRID MONOMERS AND DENTAL MATERIALS BASED THEREON

Ivoclar Vivadent AG, Sch...

1. Acidic monomer according to Formula I:
in which
A=a linear or branched aliphatic C1-C18-hydrocarbon group, which can be interrupted by one or more —O—, —S—, —CO—O—, —O—CO—NH—, —HN—CO—NH— or —CO—NR1—,
R1=H or a C1-C6 alkyl group,
X=is absent or is a linear or branched aliphatic C1-C10 hydrocarbon group, which can be interrupted by one or more —O—, —S—, —CO—O—, —O—CO—NH—, —HN—CO—NH— or —CO—NR2—,
R2=H or a C1-C6 alkyl group,
PG=a radically polymerizable group selected from vinyl, allyl, CH2?CR3—CO—Y— or R4O—CO—C(?CH2)—CH2—Y—,
Y=O or NR5 or is absent,
R3=H or CH3
R4=H or a C1-C7 alkyl group,
R5=H or a C1-C7 alkyl group,
n=1, 2, 3 or 4,
m=1 or 2,
p=1, 2 or 3, and
q=1, 2 or 3.

US Pat. No. 10,188,571

ADAPTER FOR CONNECTING AT LEAST ONE ACCESSORY DEVICE TO AN OPERATING TABLE

1. An operating table adapter, comprising: a table mount configured to removably attach the adapter to an operating table; and an accessory mount configured to attach a surgery extension device to the adapter; wherein the adapter includes a free-standing, X-ray transparent member; wherein the X-ray transparent member includes a first part comprising a lower surface configured to directly contact an upper support surface of the operating table, and a second part configured to extend beyond the upper support surface in a longitudinal direction of the upper support surface when the adapter is mounted to the operating table via the table mount; wherein the second part of the X-ray transparent member comprises a support surface extension configured to support a patient when the adapter is attached to the operating table; and the table mount comprising: a guide rod, the guide rod being elongated and extending downward with respect to the X-ray transparent member when the adapter is attached to the operating table; and an abutment element, the abutment element being movable vertically along the guide rod towards and away from the X-ray transparent member, and being lockable along the guide rod; wherein when the operating table adapter is positioned on said operating table, the abutment element is movable along the guide rod and lockable against a bottom surface of the operating table, to thereby grasp the operating table between the first part of the X-ray transparent member and the abutment element.

US Pat. No. 10,188,562

DISPOSABLE DIAPER AND A METHOD OF MANUFACTURING A DISPOSABLE DIAPER

UNICHARM CORPORATION, Eh...

1. A disposable diaper, comprising:a front waistline region, a rear waistline region, a crotch region positioned between the front waistline region and the rear waistline region;
a product longitudinal direction from the front waistline region towards the rear waistline region, and a product widthwise direction perpendicular to the product longitudinal direction;
a skin-surface side sheet adapted to face toward a body of a wearer when the diaper is worn;
a non-skin surface side sheet adapted to face away from the body of the wearer when the diaper is worn;
an absorber arranged between the skin-surface side sheet and the non-skin surface side sheet, running across the crotch region in the product longitudinal direction, and extending from the crotch region to at least either one of the front waistline region and rear waistline region;
a waistline retaining unit disposed in the front and rear waistline regions and adapted to hold the disposable diaper onto the body of the wearer;
leg stretching units arranged along leg hole openings provided on an outer side of the absorber in the product widthwise direction, said leg stretching unit being configured to expand and contract along the product longitudinal direction; and
diaper ends defining an outer circumference of the disposable diaper,
wherein
the leg stretching units are arranged between the skin-surface side sheet and the non-skin surface side sheet,
in a plan view of the disposable diaper, the leg stretching units are arranged on an inner side of the diaper ends in the product longitudinal direction or on the inner side of the diaper ends in the product widthwise direction,
the leg stretching units have ends opposing each other in the product longitudinal direction,
a part of the waistline retaining unit is arranged in at least one of
a first region on an outer side in the product longitudinal direction from the ends of the leg stretching units, or
a second region on an outer side in the product widthwise direction from the ends of the leg stretching units,
a joint region where the skin-surface side sheet and the non-skin surface side sheet are joined is provided along the diaper ends in at least one of the first region or the second region,
a first adhesive is applied at an interval, on the skin-surface side sheet of the first region and the second region, based on a first application pattern, and
a second adhesive is applied at an interval, on the non-skin surface side sheet of the first region and the second region, based on a second application pattern different from the first application pattern.

US Pat. No. 10,188,555

SHEAR RESISTANT WOUND DRESSING FOR USE IN VACUUM WOUND THERAPY

1. A negative pressure wound therapy dressing comprising:a backing layer comprising a flexible polymeric membrane, the backing layer including a lower wound facing side, an upper side opposite the lower wound facing side, and an aperture extending through the backing layer;
a porous layer disposed below the lower wound facing side of the backing layer;
an absorbent filler, wherein the absorbent filler is configured to be in fluid communication with the porous layer and configured to collect exudate removed from a wound; and
a vacuum port configured to be fluidically connected, via a tube, to a negative pressure source, wherein the vacuum port comprises:
a flange having an underside and a top side, wherein the underside of the flange has an opening positioned over the aperture in the backing layer and the underside of the flange is positioned on the upper side of the backing layer; and
a connector extending above the flange, the connector configured to be connected to the tube;
a screen positioned across the opening on the underside of the flange configured to prevent migration of particles into the vacuum port, wherein the screen comprises openings having a size configured to prevent migration of particles into the vacuum port, the size of the openings being large enough for liquid wound exudate to pass through the screen.

US Pat. No. 10,188,513

PROSTHETIC TISSUE VALVES

CORMATRIX CARDIOVASCULAR,...

1. A prosthetic valve for modulating fluid flow through a cardiovascular structure during cardiac cycles of a heart, said fluid flow exhibiting a plurality of positive and negative flow pressures during said cardiac cycles, said prosthetic valve comprising:a valve structure comprising a remodelable conical shaped sheet member, said sheet member comprising an extracellular matrix (ECM) composition, said ECM composition comprising acellular ECM from a mammalian tissue source,
said sheet member further comprising an open proximal annulus engagement end configured to engage said cardiovascular structure and receive said fluid flow therein and a closed distal end,
said sheet member further comprising a plurality of linear interstices disposed between said sheet member open proximal annulus engagement end and said closed distal end, wherein said plurality of linear interstices do not extend to said closed distal end,
said sheet member being configured to transition from an expanded position when said proximal annulus engagement end of said sheet member is engaged to said cardiovascular structure and receives said fluid flow therein, and said fluid flow exhibits a first positive flow pressure of said plurality of positive flow pressures, to a collapsed position when said fluid flow exhibits a first negative flow pressure of said plurality of negative flow pressures,
said plurality of linear interstices being configured to transition from an open position, when said sheet member is in said expanded position, to a closed position, when said sheet member is in said collapsed position,
said closed distal end of said sheet member being configured to block said fluid flow therethrough when said plurality of linear interstices are in said open and closed positions, wherein when said plurality of linear interstices are in said open position, said plurality of linear interstices allow said fluid flow to be transmitted through said plurality of linear interstices and sheet member, and wherein when said plurality of linear interstices are in said closed position, said plurality of linear interstices and said closed distal end of said sheet member jointly block said fluid flow through said sheet member,
said sheet member being further configured to remodel, and induce host cell and tissue proliferation, remodeling of damaged cardiovascular tissue and regeneration of new cardiovascular tissue and tissue structures with site-specific structural and functional properties, when said proximal annulus engagement end of said sheet member is engaged to said cardiovascular structure, wherein said proximal annulus engagement end of said sheet member is disposed proximate damaged tissue of said cardiovascular structure; and
a biodegradable multi-link support stent structure disposed in said sheet member.

US Pat. No. 10,188,510

PROSTHETIC TISSUE VALVES

CorMatrix Cardiovascular,...

1. A prosthetic valve for modulating fluid flow through a cardiovascular structure during cardiac cycles of a heart, said fluid flow exhibiting a plurality of positive and negative flow pressures during said cardiac cycles, said prosthetic valve comprising:a remodelable biological tissue structure comprising a continuous tubular member,
said tubular member comprising an adaptive tissue regeneration system configured to engage said cardiovascular structure and induce modulated healing of damaged cardiovascular tissue of said cardiovascular structure concomitantly with stress-induced hypertrophy of said tubular member when said tubular member is subjected to cardiac cycle induced physical stimuli,
said modulated healing of said damaged cardiovascular tissue comprising inflammation modulation of said damaged cardiovascular tissue and induced neovascularization, remodeling of said damaged cardiovascular tissue and regeneration of new cardiovascular tissue and tissue structures with site-specific structural and functional properties,
said stress-induced hypertrophy of said tubular member comprising adaptive remodeling of said tubular member, wherein said tubular member remodels and forms functioning valve structures that are similar to native valve structures,
said adaptive tissue regeneration system comprising a tubular member material component and a tubular member physical structure component,
said tubular member material component comprising an extracellular matrix (ECM) composition, said ECM composition comprising acellular ECM from a mammalian tissue source,
said tubular member physical structure component comprising a sheet member comprising a proximal valve annulus engagement end and a distal end, said proximal valve annulus engagement end of said sheet member being configured to engage a valve annulus region of said cardiovascular structure,
said proximal valve annulus engagement end comprising a circumferential ribbon connection region and a plurality of equally spaced ribbons projecting from said circumferential ribbon connection region toward said sheet member distal end,
each of said plurality of ribbons comprising proximal and distal ends, a first edge region extending from said proximal end of each of said plurality of ribbons to said distal end of each of said plurality of ribbons and a second edge region extending from said proximal end of each of said plurality of ribbons to said distal end of each of said plurality of ribbons,
said proximal end of each of said plurality of ribbons being connected to said circumferential ribbon connection region,
said plurality of ribbons being positioned circumferentially about said circumferential ribbon connection region, wherein said first edge regions of said plurality of ribbons are positioned proximate said second edge regions of said plurality of ribbons, wherein a plurality of fluid flow modulating regions is formed between adjacent ribbons of said plurality of ribbons,
said distal ends of said plurality of ribbons being engaged to each other in a joined relationship, wherein fluid flow through said sheet member at said joined distal ends of said plurality of ribbons is restricted while said fluid flow is allowed to be transmitted through said fluid flow modulating regions when in an open position,
said sheet member being configured to transition from an expanded position when said proximal valve annulus engagement end of said sheet member is engaged to said valve annulus region of said cardiovascular structure and receives said fluid flow therein, and said fluid flow exhibits a first positive flow pressure of said plurality of positive flow pressures, to a collapsed position when said fluid flow exhibits a first negative flow pressure of said plurality of negative flow pressures,
said plurality of fluid flow modulating regions being configured to transition from said open position when said sheet member is in said expanded position, wherein said plurality of fluid flow modulating regions allow said fluid flow to be transmitted through said sheet member, to a closed position when said sheet member is in said collapsed position, wherein said plurality of fluid flow modulating regions restrict said fluid flow through said sheet member.

US Pat. No. 10,188,509

PROSTHETIC TISSUE VALVES

CORMATRIX CARDIOVASCULAR,...

1. A prosthetic valve for modulating fluid flow through a cardiovascular structure during cardiac cycles of a heart, said fluid flow exhibiting a plurality of positive and negative flow pressures during said cardiac cycles, said prosthetic valve comprising:a remodelable biological tissue structure comprising a conical shaped sheet member, said sheet member comprising an extracellular matrix (ECM) composition, said ECM composition comprising acellular ECM from a mammalian tissue source,
said sheet member further comprising an open proximal annulus engagement end configured to engage said cardiovascular structure and receive said fluid flow therein and a closed distal end,
said sheet member further comprising a plurality of linear interstices disposed between said sheet member open proximal annulus engagement end and said closed distal end, wherein said plurality of linear interstices do not extend to said closed distal end,
said sheet member being configured to transition from an expanded position when said proximal annulus engagement end of said sheet member is engaged to said cardiovascular structure and receives said fluid flow therein, and said fluid flow exhibits a first positive flow pressure of said plurality of positive flow pressures, to a collapsed position when said fluid flow exhibits a first negative flow pressure of said plurality of negative flow pressures,
said plurality of linear interstices being configured to transition from an open position, when said sheet member is in said expanded position, to a closed position, when said sheet member is in said collapsed position,
said closed distal end of said sheet member being configured to block said fluid flow therethrough when said plurality of linear interstices are in said open and closed positions, wherein when said plurality of linear interstices are in said open position, said plurality of linear interstices allow said fluid flow to be transmitted through said plurality of linear interstices and said sheet member, and wherein when said plurality of linear interstices are in said closed position, said plurality of linear interstices and said distal end of said sheet member jointly block said fluid flow through said sheet member,
said sheet member being further configured to remodel, and induce host cell and tissue proliferation, remodeling of damaged cardiovascular tissue and regeneration of new cardiovascular tissue and tissue structures with site-specific structural and functional properties, when said proximal annulus engagement end of said sheet member is engaged to said cardiovascular structure, wherein said proximal annulus engagement end of said sheet member is disposed proximate damaged tissue of said cardiovascular structure.

US Pat. No. 10,188,500

STENT GRAFT WITH EXTERNAL SCAFFOLDING AND METHOD

Medtronic Vascular, Inc.,...

1. A scaffolded stent-graft comprising:a hydrophobic graft material comprising an inner surface and an outer surface, the inner surface defining a lumen within the graft material, the graft material being hostile to tissue ingrowth therein; and
a scaffold comprising a metallic material mesh comprising openings therein coupled to the graft material at the outer surface, the scaffold configured to promote tissue ingrowth therein, the scaffold comprising a metal to artery ratio optimized to create stasis of blood within the scaffold resulting in thrombus formation, wherein the mesh is in the shape of a torus.

US Pat. No. 10,188,496

VENA CAVA FILTER FORMED FROM A SHEET

C. R. BARD, INC., Murray...

1. A blood filter for use in a patient's blood vessel having a vessel wall surrounding a vessel lumen, comprising:a) a longitudinally extending filter body including a proximal section extending a first fixed distance from a proximal terminal end of the longitudinal filter body to a first intermediate endpoint, said proximal section having a first cross-sectional area;
b) a distal section having a distal terminal end and a second cross-sectional area;
c) a joining section positioned between the proximal and distal sections and having a third cross-sectional area less than both the first and second cross-sectional areas;
d) said joining section spaced away from each of said terminal ends and extending a fixed second distance;
e) a first hub on said joining section that is slidable a fixed distance along a length of said joining section and in between said proximal and distal sections while in use in the blood vessel;
f) a plurality of appendages, each attached to said hub at an inner appendage end portion, each appendage having an outer appendage end portion providing unattached distal-most ends extending radially outward of said hub;
g) wherein said appendages are bendable in both a proximal and distal direction, thus enabling insertion of said filter body with hub and appendages using either a jugular access site or a femoral access site; and
h) wherein said filter body, said hub and said appendages are configured to occupy a vessel of a patient.

US Pat. No. 10,188,492

NAPKIN BAND WITH DENTAL FLOSS

1. A napkin band, the napkin band comprising:a generally rectangular portion;
a sealed pocket located generally along the length of the rectangular portion;
a length of dental floss located inside the sealed pocket; and
wherein the sealed pocket is formed from a portion of the generally rectangular portion folded back upon the rectangular portion, and where the sealed pocket is sealed along its length and ends by an adhesive.

US Pat. No. 10,188,457

SELECTABLE ECCENTRIC REMODELING AND/OR ABLATION

Vessix Vascular, Inc., L...

1. An apparatus comprising:a catheter configured for intravascular placement within a blood vessel of a human patient;
an expandable balloon at a distal portion of the catheter, wherein the expandable balloon is configured to vary between a delivery configuration and a deployed configuration sized to fit within the blood vessel;
a first pair of bipolar contacts attached to the expandable balloon; and
a second pair of bipolar contacts attached to the expandable balloon,
wherein the first pair of bipolar contacts and the second pair of bipolar contacts are spaced apart lengthwise and angularly offset from one another when the expandable balloon is in the deployed configuration,
wherein each of the first pair of bipolar contacts and the second pair of bipolar contacts is configured to deliver thermal energy to less than a full circumference of the blood vessel of the patient.

US Pat. No. 10,188,447

ELECTROSURGICAL SYSTEM

GYRUS MEDICAL LIMITED, C...

1. An electrosurgical system comprising:an electrosurgical generator;
a source of ionisable gas;
a controller; and
an electrosurgical instrument, the electrosurgical generator including a source of RF energy, the system also including a first connector and the electrosurgical instrument including a second connector,
the first connector being configured to connect with the second connector,
the first connector comprising a first set of at least three connector components,
the second connector comprising a second set of at least three connector components,
each of the three connector components of the first set being configured to connect to and disconnect from a respective one of the at least three connector components of the second set,
a connection between the first connector component of the first set and the first connector component of the second set is configured to allow the electrosurgical generator to deliver an RF energy output from the source of RF energy to the electrosurgical instrument,
a connection between the second connector component of the first set and the second connector component of the second set is configured to allow the source of ionisable gas to deliver a supply of ionisable gas to the electrosurgical instrument,
a connection between the third connector component of the first set and the third connector component of the second set is configured to allow the controller to identify the electrosurgical instrument, and
the third connector component of the first set being configured to connect to the third connector component of the second set only after the first connector component of the first set is connected to the first connector component of the second set and the second connector component of the first set is connected to the second connector component of the second set, wherein the controller is adapted to inhibit the supply of RF energy until after the controller has successfully identified the electrosurgical instrument.

US Pat. No. 10,188,441

DRUG DELIVERY IMPLANT IMPLANTED INTO BONE

UNIVERSITY-INDUSTRY COOPE...

1. A drug delivery implant configured to be implanted into a bone, comprising:a hollow implant fixture provided with an inlet formed at an upper end thereof; and
a drug supply cartridge coupled to the hollow implant fixture,
wherein the drug supply cartridge includes:
a cap for closing the inlet of the hollow implant fixture; and
a cartridge main body provided under the cap, coupled with the cap so as to be mounted in the hollow implant fixture integrally with the cap, and accommodated in the hollow implant fixture to release a drug,
wherein a cartridge hole to accommodate the cartridge main body and drug channels to guide a drug released from the inside of the cartridge main body to the outside of the hollow implant fixture are formed in the hollow implant fixture,
wherein the cartridge main body includes:
an outer membrane including first release holes to release the drug to the outside of the cartridge main body and forming an outer cover of the cartridge main body; and
an inner membrane including second release holes closed by the outer membrane, stacked in the outer membrane and closing the first release holes, the first release holes and the second release holes being selectively communicable with each other by an external force applied to the cartridge main body.

US Pat. No. 10,188,435

INSTRUMENTS AND METHODS FOR TENSIONING A SPINAL TETHER

DEPUY SYNTHES PRODUCTS, I...

1. A tether tensioning device, comprising:an elongate shaft adapted to be positioned adjacent to a bone anchor implanted in bone;
a tensioning arm pivotally connected to a plate such that the pivot point of the tensioning arm is offset from the elongate shaft, the tensioning arm being adapted to couple to a tether seated across the bone anchor and to pivot past a longitudinal axis of the elongate shaft to apply a tensioning force to the tether; and
an overload mechanism disposed within the elongate shaft and coupled to the plate, wherein the overload mechanism is configured to prevent the applied tensioning force from exceeding a threshold force.

US Pat. No. 10,188,432

SNAP-ON MULTI-PLANAR AND MONO-PLANAR RECEIVER ASSEMBLIES HAVING INTEGRAL AND MULTI-PART MULTIPURPOSE POSITIONERS FOR PIVOTING AND NON-PIVOTING RETAINERS

16. A pivotal bone anchor assembly for securing an elongate rod to a bone, the bone anchor assembly comprising:a bone anchor having a capture portion and an integral anchor portion extending distally from the capture portion for fixation to the bone;
a receiver comprising a base defining a cavity having a bottom opening in communication with a bottom surface of the base and a pair of integral arms extending upwardly from the base to define a U-shaped channel configured to receive the elongate rod, the U-shaped channel being in communication with the cavity and the cavity having an internal circumferential recess above the bottom opening;
a retainer expandable within the circumferential recess and having an inner surface operable to capture the bone anchor capture portion; and
a positioner disposed within the receiver cavity and engaged with the retainer to stabilize and centralize the retainer within the receiver cavity above a lower portion of the cavity adjacent the bottom opening and entirely spaced from internal surfaces of the receiver cavity, prior to receiving the capture portion of the bone anchor,
wherein, upon insertion of the bone anchor capture portion into the receiver cavity through the bottom opening, the retainer is released from the positioner and moved to the lower portion of the cavity, thereby allowing the retainer inner surface to capture and hold the bone anchor capture portion within the receiver cavity.

US Pat. No. 10,188,427

SPINAL CONSTRUCT AND METHOD

Warsaw Orthopeic, Inc., ...

1. A spinal construct comprising:a connector extending along a longitudinal axis between a first end and a second end, the first end comprising a passageway, a shaft of the second end being positioned within the passageway such that the second end can translate relative to the first end along the longitudinal axis, the ends each comprising a threaded hole extending through a top surface of the connector,
wherein the first end comprises a first expandable member including an inner surface defining a cavity configured to receive a head of a first bone fastener and the second end comprises a second expandable member including an inner surface defining a cavity configured to receive a head of a second bone fastener, the cavities each including an opening extending through a bottom surface of the connector, the expandable members each comprising a retaining member positioned in a respective one of the cavities, an inner locking ring positioned in a respective one of the cavities and a notch that extends into a respective one of the inner surfaces, the openings each having a maximum diameter greater than a maximum diameter of each of the retaining members, the retaining members being configured to expand radially and then collapse back to their original form when one of the heads contacts one of the retaining members, the inner locking rings being configured to be pushed into one of the notches when one of the heads is received by one of the retaining members.

US Pat. No. 10,188,422

BIOPSY NEEDLE DESIGN

3DBiopsy, Inc., Aurora, ...

1. An apparatus, comprising:a cannula, comprising:
a tubular body extending between a first end and a second end, the tubular body having a first side and an opposite second side; and
a leading edge formed at the first end, the leading edge extending along a first plane, the first plane extending between the first side and second side, the first plane forming a leading edge angle between the intersection of the first side and the first plane, wherein the leading edge angle is between 12 degrees and 20 degrees;
a mandrel, comprising:
a body extending between a first end and a second end;
a trocar point formed by the first end;
a notch formed by the body, the notch forming a bed extending between the first end and the second end;
a first sample region formed by the bed, the first sample region, comprising:
a first plurality of ridges, wherein each of the first plurality of ridges comprises:
a flank extending from the bed toward the second end, the flank terminating at a crest;
a second sample region formed by the bed, the second sample region comprising:
a second plurality of ridges, wherein each of the second plurality of ridges comprises:
a flank extending from the bed toward the second end, the flank terminating in a crest; and
a concave slope descending from the crest; and
a deck disposed between the first plurality of ridges and the second plurality of ridges;
a cannula force source imparting movement to the cannula, wherein the cannula force source imparts a loaded force between 7 lbs. and 11 lbs.

US Pat. No. 10,188,410

POWER PARAMETERS FOR ULTRASONIC CATHETER

EKOS CORPORATION, Bothel...

1. A method of operating an ultrasonic catheter comprising:advancing a catheter with at least one ultrasonic element to a treatment site in a patient's vascular system;
driving the at least one ultrasonic element to generate ultrasonic energy;
delivering a therapeutic compound to the treatment site through the catheter; and
non-linearly varying a power parameter of the at least one ultrasonic element, wherein the power parameter is selected from the group consisting of peak power, pulse repetition frequency, pulse width, and pulse repetition interval,
wherein the peak power is randomly or pseudo randomly distributed between a bounded maximum peak power Pmax and a bounded minimum peak power Pmin,
wherein the pulse repetition frequency is varied randomly between a bounded maximum pulse repetition frequency and a bounded minimum pulse repetition frequency,
wherein the pulse width is varied randomly within a bounded range, and
wherein the pulse repetition interval is varied randomly within a bounded range.

US Pat. No. 10,188,409

ASPIRATION THROMBECTOMY CATHETER SYSTEM, AND ASSOCIATED METHODS

Smalling Medical Ventures...

1. A method for aspirating a thrombus from a vessel, the thrombus having at least a first portion and a second portion, wherein the first portion is within an innermost layer of the thrombus and the second portion is within a medial or an intimal layer of the thrombus, the method comprising the steps of:inserting an aspiration catheter into the vessel, the aspiration catheter having a first lumen and a second lumen disposed therein, a tapering distal end and a plurality of aspiration port sets arranged along the tapering distal end, each of the plurality of aspiration port sets having a plurality of ports for aspirating thrombus from the vessel, and wherein at least one of the plurality of aspiration port sets is in fluidic communication with the first lumen and at least another one of the plurality of aspiration port sets are in fluidic communication with the second lumen;
advancing the aspiration catheter within the vessel until an aspiration port set closest to a tip of the tapering distal end of the aspiration catheter is proximate the first portion of the thrombus;
applying aspiration forces through at least the aspiration port set closest to the tip of the tapering distal end of the aspiration catheter to suction at least the first portion of the thrombus into the first lumen;
advancing the aspiration catheter through the thrombus until the aspiration port set closest to the tip of the tapering distal end of the aspiration catheter is proximate to the second portion of the thrombus; and
applying aspiration forces through an aspiration port set disposed closest to a proximal end of the tapering distal end of the aspiration catheter to suction at least the second portion of the thrombus into at least one of the first and second lumens;
wherein each of the plurality of ports comprising the aspiration port set closest to the tip of the tapering distal end of the aspiration catheter is smaller in size than each of the plurality of ports comprising the aspiration port set disposed closest to the proximal end of the tapering distal end of the aspiration catheter.

US Pat. No. 10,188,408

GLENOID CAVITY BONE PREPARATION SET FOR SETTING A SHOULDER PROSTHESIS, AND METHOD FOR IMPLANTING A SHOULDER PROSTHESIS

FOURNITURES HOSPITALIERES...

1. A glenoid cavity bone preparation set for setting a shoulder prosthesis, comprising:a drill guide comprising:
a bearing surface intended to bear against a glenoid cavity of a scapula which has been prepared beforehand,
a passage orifice opening into the bearing surface of the drill guide and intended for the passage of a guide pin implanted in the glenoid cavity, and
a first guide orifice and a second guide orifice each opening into the bearing surface of the drill guide and each intended to guide a drill bit capable of realizing a bone bore in the glenoid cavity, the first and second guide orifices being inclined with respect to an extension axis of the passage orifice of the drill guide and converging in the direction of the bearing surface of the drill guide,
a compactor comprising a compaction portion having a generally trapezoidal shape and intended to be impacted against the glenoid cavity so as to form a bone housing in the glenoid cavity, the compactor further including a passage hole extending at least partially in the compaction portion and intended for the passage of the guide pin implanted in the glenoid cavity.

US Pat. No. 10,188,407

DRILL GUIDE FOR ACETABULAR CUP FASTENERS

HIP INNOVATION TECHNOLOGY...

1. A surgical tool system adapted for drilling holes in an acetabulum to accommodate screws used to fasten an acetabular cup to the acetabulum, the acetabular cup comprising a concave portion having a stem extending from the bottom thereof, cup slots disposed in the concave portion in close proximity to a circumferential edge of the acetabular cup and one or more through holes to accommodate screws for fastening the acetabular cup to the acetabulum, the surgical tool system comprising:a drill guide sized to fit within the concave portion and having spring-loaded pins arranged to engage the cup slots when the drill guide is optimally positioned within the acetabular cup, the drill guide further comprising one or more through holes sized and spaced to line up approximately concentrically with the through holes of the acetabular cup and a guide indent for each hole, each guide indent being positioned on a beam member which traverses the drill guide at a circumferential edge thereof;
a handle comprising a shaft with a drill bit guide disposed at the distal end thereof, the drill bit guide having a drill bit guide distal end and a side portion, the drill bit guide being sized to engage a hole and the side portion being positioned to engage the guide indent for its respective hole; and
a drill bit having a cutting portion and a shaft sized to pass through the drill bit guide.

US Pat. No. 10,188,372

SURGICAL INSTRUMENT GUIDE DEVICE

Cambridge Endoscopic Devi...

1. A surgical instrument assembly comprising:a manually operated instrument that includes;
an elongated instrument shaft having proximal and distal ends,
a control handle,
a proximal motion member that connects the control handle to the proximal end of the elongated instrument shaft,
an end effector,
a distal motion member that connects the distal end of the elongated instrument shaft to the end effector,
a guide member for receiving the instrument shaft, having proximal and distal ends and including;
a guide shaft,
a distal motion means at the distal end of said guide shaft,
a proximal motion means at the proximal end of said guide shaft; and
actuation means extending between said distal and proximal motion means so that any deflection of said proximal motion means causes a corresponding deflection of said distal motion means for control of said end effector, said end effector extending beyond the distal motion means at an operative site.

US Pat. No. 10,188,355

BACKGROUND-SUPPRESSED, REDUCED FIELD-OF-VIEW RADIAL MAGNETIC RESONANCE IMAGING

Siemens Healthcare GmbH, ...

1. A computer-implemented magnetic resonance imaging (MRI) method for acquiring images of a patient, the method comprising:receiving, by an input processor, user input comprising an indication of a field of view (FOV) that encompasses only an anatomy of interest of the patient, the anatomy of interest smaller than a full dimension of the patient;
shimming, by a processor configured to communicate with the input processor, on the anatomy of interest within the FOV;
applying, by the processor, a radial quiescent-interval slice-selective (QISS) pulse sequence including a magnetization preparation pulse to the shimmed FOV to acquire images of the anatomy of interest; and
generating, at a display processor configured to communicate with the processor, data representing the acquired images of the anatomy of interest.

US Pat. No. 10,188,341

METHOD AND DEVICE FOR DETECTING SPEECH PATTERNS AND ERRORS WHEN PRACTICING FLUENCY SHAPING TECHNIQUES

Novotalk, Ltd., Tel-Aviv...

1. A method for detecting errors when practicing fluency shaping exercises, comprising:receiving a set of initial energy levels;
setting each threshold of a set of thresholds to a respective predetermined initial value;
receiving a voice production of a user practicing a fluency shaping exercise;
analyzing the received voice production to compute a set of energy levels composing the voice production;
detecting at least one speech-related error based on the computed set of energy levels, the set of initial energy levels, and the set of a thresholds, wherein the detection of the at least one speech-related error is with respect to the fluency shaping exercise being practiced by the user; wherein the set of initial energy levels includes at least one of: a normal speech energy level, a silence energy level, and a calibration energy level,
upon detection of the at least one speech-related error, generating visual feedback indicating the at least one detected speech-related error with respect to the received voice production, and
performing an audio calibration process for a computing device of the user to set the normal speech energy level, the silence energy level, and the calibration energy level, wherein the voice production is captured on the computing device of the user,
wherein processing the received voice production further comprises: sampling the received voice production to create voice samples; buffering the voice samples to create voice chunks; converting the voice chunks from a time domain to a frequency domain; extracting spectrum features from each of the frequency domain voice chunks, wherein the spectrum features include at least dominant frequencies, wherein each dominant frequency corresponds to a voice chunk; computing, for each voice chunk, the energy level of the corresponding dominant frequency; and determining, for each voice chunk, an energy level of the voice chunk based on the energy level of the corresponding dominant frequency.

US Pat. No. 10,188,335

PLASMA OR SERUM PRODUCTION AND REMOVAL OF FLUIDS UNDER REDUCED PRESSURE

Seventh Sense Biosystems,...

21. A device for receiving blood from a subject and processing the blood to form plasma or serum, the device comprising:an inlet for introduction of a bodily fluid from the subject into the device;
a storage chamber for receiving plasma or serum;
a first membrane that is substantially impermeable to cells, wherein the first membrane separates the inlet from the storage chamber and is capable of separating blood passing through to produce a portion enriched in plasma or serum;
a vacuum chamber, separate from the storage chamber, having a pressure less than ambient pressure; and
a second membrane that is gas permeable but is substantially liquid impermeable, wherein the second membrane separates the storage chamber from the vacuum chamber.

US Pat. No. 10,188,332

METHOD AND SYSTEM FOR SENSING GLUCOSE CONCENTRATION

NATIONAL CHENG KUNG UNIVE...

1. A system for sensing glucose concentration, the system comprising:a light source configured to generate a light beam;
a polarization state generator configured to receive the light beam, wherein the polarization state generator comprises a modulator for changing a polarization of the light beam, and the light beam passing the modulator is emitted to a biological tissue;
a polarization state analyzer configured to receive the light beam reflected from the biological tissue; and
a controlling module configured to transmit an electrical signal to the modulator, wherein the electrical signal has n sampling points which correspond to n polarizations of the light beam respectively, the n polarizations are different from each other, and n is a positive integer greater than or equal to 4,
wherein for each of the n sampling points, the controlling module calculates a Stokes vector according to the light beam received by the polarization state analyzer,
wherein the controlling module calculates a Mueller matrix according to the Stokes vectors corresponding to the n sampling points, and calculates at least one parameter according to the Mueller matrix, wherein the at least one parameter comprises a depolarization index or an optical rotation angle,
wherein the controlling module calculates a glucose concentration corresponding to the biological tissue according to the at least one parameter.

US Pat. No. 10,188,331

NON-INVASIVE PHYSIOLOGICAL SENSOR COVER

MASIMO CORPORATION, Irvi...

1. A partially opaque sensor cover for use with a pulse oximeter sensor, the partially opaque sensor cover comprising:a partially opaque portion attachable to the sensor and configured to block optical readings by the sensor; and
a tab portion that protrudes from the sensor to facilitate removal of the partially opaque sensor cover,
wherein the sensor comprises:
a light source configured to emit light from one or more emitters of the sensor; and
a detector configured to receive at least a portion of the light emitted by the one or more emitters after the light has passed through a tissue site, and
wherein the partially opaque portion at least partially prevents the detector from receiving light during sensor activation.

US Pat. No. 10,188,328

NON-INVASIVE BIOLIPID CONCENTRATION METER, NON-INVASIVE BIOLIPID METABOLISM MEASURING DEVICE, NON-INVASIVE METHOD FOR MEASURING BIOLIPID CONCENTRATION, AND NON-INVASIVE METHOD FOR EXAMINING BIOLIPID METABOLISM

NATIONAL UNIVERSITY CORPO...

1. A non-invasive biolipid concentration measuring device configured to non-invasively measure a blood lipid concentration in a living body, the non-invasive biolipid concentration measuring device comprising:an irradiator configured to emit consecutive light through the living body, the light having a light intensity and wavelength being either 580 nm to 1400 nm or 1500 nm to 1860 nm, toward an irradiation position;
a light intensity detector configured to receive, detect and measure light emitted from the irradiator, the light intensity detector being disposed at a detection position separated by a given distance from the irradiation position, the light intensity detector detecting and measuring the light intensity of the light at the detection position;
a scattering coefficient calculator configured to calculate a light scattering coefficient based on the light intensity detected by the light intensity detector; and
a lipid concentration calculator configured to calculate the blood lipid concentration based on the light scattering coefficient calculated by the scattering coefficient calculator,
wherein, regardless of whether an absorption coefficient is known or unknown, the scattering coefficient calculator calculates a light scattering coefficient of the living body from a gradient of a line obtained by linearizing an attenuation rate of the light intensity with respect to the irradiation-detection distance between the irradiation position and the light intensity detector, and
the scattering coefficient calculator calculates scattering coefficient ?s? by applying light intensity R (?) detected by the light intensity detector and the irradiation-detection distance ? into Expression (1) and Expression (2)

where ?a represents the absorption coefficient, ?eff represents an effective attenuation coefficient, and S0 represents the light intensity of light emitted by the irradiator.

US Pat. No. 10,188,327

PORTABLE CLINICAL ANALYSIS SYSTEM FOR HEMATOCRIT MEASUREMENT

Abbott Point of Care Inc....

1. A method of performing a hematocrit analysis, the method comprising:inserting a test device comprising a hematocrit sensor into a port of an analyzer;
initiating, by the analyzer, a test cycle of the test device, the test cycle including performance of the hematocrit analysis, wherein the performance of the hematocrit analysis includes the test device generating an electric signal based on a hematocrit measurement of a biological sample;
determining spatial orientation and/or motion of the analyzer during the test cycle of the test device;
comparing the determined spatial orientation to a threshold operating spatial plane for the test device and/or comparing the determined motion to a threshold rate of motion for the test device;
when the determined spatial orientation exceeds the threshold operating spatial plane, and/or the determined motion exceeds the threshold rate of motion, providing an alert prompting a user to take corrective action,
wherein the corrective action is instructed in the alert to be taken during the test cycle without having to reinitiate the test cycle including the performance of the hematocrit analysis.

US Pat. No. 10,188,318

BREATH DELIVERY SYSTEM AND METHOD

Invoy Holdings, LLC, Ali...

1. A mouthpiece for use with a portable electronic analyzer for detecting an analyte in a breath sample from an individual, the mouthpiece comprising:a biosensor that detects the analyte and generates a signal, the biosensor including a chemically active area where a chemical reaction takes place;
a processor, the processor configured to communicate with the biosensor;
a hydration system that is activated by the processor and then causes a plunger to release a liquid to the chemically active area of the biosensor to at least one of enhance, enable, and facilitate the chemical reaction;
a liquid sensor that determines if the liquid was delivered to the chemically active area, the liquid sensor configured to communicate with one or more of the biosensor, the processor, and the hydration system; and
hardware that transmits breath analyte data to the electronic analyzer.

US Pat. No. 10,188,309

SYSTEMS, ARTICLES, AND METHODS FOR ELECTROMYOGRAPHY SENSORS

NORTH INC., Kitchener (C...

1. A differential electromyography (“EMG”) sensor comprising:a first sensor electrode formed of an electrically conductive material;
an amplifier;
a first electrically conductive pathway that communicatively couples the first sensor electrode and the amplifier;
a first capacitor electrically coupled in series between the first sensor electrode and the amplifier in the first electrically conductive pathway;
a first resistor electrically coupled in series between the first sensor electrode and the amplifier in the first electrically conductive pathway;
a ground electrode formed of an electrically conductive material;
a second electrically conductive pathway that communicatively couples to the ground electrode;
a third electrically conductive pathway that communicatively couples the first electrically conductive pathway and the second electrically conductive pathway;
a second capacitor electrically coupled in the third electrically conductive pathway in between the first electrically conductive pathway and the second electrically conductive pathway;
a fourth electrically conductive pathway that communicatively couples the first electrically conductive pathway and the second electrically conductive pathway;
a second resistor electrically coupled in the fourth electrically conductive pathway in between the first electrically conductive pathway and the second electrically conductive pathway;
a second sensor electrode formed of an electrically conductive material;
a fifth electrically conductive pathway that communicatively couples the second sensor electrode and the amplifier;
a third capacitor electrically coupled in series between the second sensor electrode and the amplifier in the fifth electrically conductive pathway;
a third resistor electrically coupled in series between the second sensor electrode and the amplifier in the fifth electrically conductive pathway;
a sixth electrically conductive pathway that communicatively couples the fifth electrically conductive pathway and the second electrically conductive pathway;
a fourth capacitor electrically coupled in the sixth electrically conductive pathway in between the fifth electrically conductive pathway and the second electrically conductive pathway;
a seventh electrically conductive pathway that communicatively couples the fifth electrically conductive pathway and the second electrically conductive pathway; and
a fourth resistor electrically coupled in the seventh electrically conductive pathway in between the fifth electrically conductive pathway and the second electrically conductive pathway.

US Pat. No. 10,188,306

CARDIAC POTENTIAL DETECTION DEVICE AND CARDIAC POTENTIAL DETECTION METHOD

PANASONIC INTELLECTUAL PR...

1. A cardiac potential detection device for detecting R-waves from an electrocardiographic waveform, the cardiac potential detection device comprising:a plurality of electrodes;
a detector configured to detect an input voltage applied from the plurality of electrodes; and
a control unit configured to:
identify an R-wave candidate based on an R-wave detection threshold and a peak in the input voltage,
determine whether an absolute value of the input voltage is smaller than a predetermined threshold;
when the control unit determines that the absolute value of the input voltage has exceeded the predetermined threshold, calculate a detection-suspension period based on a time at which the input voltage exceeded the predetermined threshold, and suspend identifying of an R-wave candidate in the detection-suspension period, and
in a period excluding the detection-suspension period, identify the R-wave candidate as an R-wave when the input voltage does not exceed the predetermined threshold in a period from the R-wave candidate peak until a predetermined time expires.

US Pat. No. 10,188,302

METHODS FOR DYNAMIC VISUALIZATION OF CLINICAL PARAMETERS OVER TIME

The University of Vermont...

8. A non-transitory computer readable medium containing program instructions executable by a processor, the computer readable medium comprising:program instructions for generating a thrombin generation profile of a subject from measurements of the concentrations of factors II, V, VII/VIIa, VIII, IX, and X, tissue factor pathway inhibitor (TFPI), protein C (PC), and antithrombin (AT) in a biological sample from the subject;
program instructions for obtaining the parameters: maximum level of thrombin generation, maximum rate of thrombin generation, total thrombin generated, and clot time, the parameters are derived from the measurements of factors II, V, VII/VIIa, VIII, IX, and X, TFPI, PC, and AT; and
program instructions for determining the propensity of the patient for blood clotting and bleeding, the determination is based on the parameters; and
program instructions for displaying the thrombin generation profile in a visual form;
wherein a thrombin generation profile comprising a greater than 3-fold decrease in clot time and greater than 3-fold increase in maximum level of thrombin generation, maximum rate of thrombin generation, and total thrombin generated, relative to a respective reference for each of said parameters comprising the thrombin generation profile, indicates a propensity of the subject for blood clotting; and
wherein a thrombin generation profile comprising a greater than 3-fold increase in clot time and a greater than 3-fold decrease in maximum level of thrombin generation, maximum rate of thrombin generation, and total thrombin generated, relative to the respective reference for each of said parameters comprising the thrombin generation profile, indicates a propensity of the subject for bleeding.

US Pat. No. 10,188,298

OPTICAL SPECULUM

Illumigyn Ltd., Neve Ila...

1. A system for direct imaging, diagnosing and removing of abnormal cells in a target tissue, comprising:a disposable optical speculum;
an image acquisition system having the speculum assembled on and mechanically secured thereto, the image acquisition system arranged to capture at least one of a single image or multiple images or video of cells within the target tissue using at least one of bright field or dark field ring illumination divided into independently operated segments to obtain a plurality of data sets;
an image analysis and control unit in communication with the image acquisition system, the image analysis and control unit analyzing the data sets and applying algorithms to the data sets for diagnosing abnormal cells; and
a detector for warning of undesired stray light generated by improper assembly of the disposable optical speculum to the image acquisition system.

US Pat. No. 10,188,297

INTRA-OPERATIVE MOLECULAR IMAGING

Case Western Reserve Univ...

1. A system for detecting tumor margins, comprising:a topical protease-specific, near infrared fluorescence (NIRF) imaging probe that is activatable by enzymatic activation to produce a visually differentiated signal upon topical application to a targeted cancer cell that secretes an enzyme that activates the protease-specific, NIRF imaging probe, wherein the protease-specific, NIRF imaging probe is activated by binding to the enzyme secreted by the cancer cell;
means for topically administering the protease-specific, NIRF imaging probe to the cancer cell; and
an imaging device to detect activation of the protease-specific, NIRF imaging probe administered to the cancer cell to detect tumor margins.

US Pat. No. 10,188,296

WIRELESS PATIENT MONITORING DEVICE

Masimo Corporation, Irvi...

1. A method of wirelessly monitoring physiological information, the method comprising:providing a battery including a data storage component;
connecting the battery to a bedside monitor;
recharging the battery via the bedside monitor;
upon connecting the battery to the bedside monitor, transferring wireless communication configuration data from the bedside monitor to the data storage component via a hard wired connection;
disconnecting the battery from the bedside monitor;
connecting the disconnected battery to a wireless monitor;
powering the wireless monitor with the battery;
upon connecting the disconnected battery to the wireless monitor, transferring the wireless communication configuration data from the data storage component to the wireless monitor;
reconfiguring wireless communication parameters of the wireless monitor according to the wireless communication configuration data when the battery is connected to the wireless monitor;
establishing wireless communication between the wireless monitor and the bedside monitor using the wireless communication configuration data;
obtaining physiological information from one or more optical sensors using the wireless monitor powered by the battery; and
transmitting physiological data reflective of the physiological information from the wireless monitor to the bedside monitor.

US Pat. No. 10,188,295

INTEGRATED SENSOR NETWORK METHODS AND SYSTEMS

The Curators of the Unive...

1. A method comprising:processing sensor data from a plurality of motion sensors and a bed sensor deployed in a living unit for a first time period to establish a frame of reference for an activity pattern by a person residing in the living unit, wherein the activity pattern frame of reference represents a health condition of a person residing in the living unit, wherein the processed sensor data for the first time period comprises a plurality of data values corresponding to a plurality of subintervals within the first time period, wherein each subinterval data value represents (1) a total number of sensor hits during that subinterval of the first time period or (2) a total time for sensor firings during that subinterval of the first time period, and wherein the activity pattern frame of reference comprises a statistical value about the subinterval data values over the first time period;
computing a standard deviation for the processed sensor data over the first time period based on the subinterval data values;
defining a statistical parameter threshold, wherein the statistical parameter threshold comprises a defined number of the standard deviations;
processing additional sensor data from the plurality of motion sensors and the bed sensor deployed in the living unit for a second time period, the second time period occurring after the first time period;
computing a value for the activity pattern for the second time period based on the processed additional sensor data, the computed activity pattern value of the second time period also representing a health condition of the person, wherein the computed activity pattern value comprises (1) data about a total number of sensor hits during the second time period if the activity pattern frame of reference is based on the total number of sensor hits during the first time period or (2) data about a total time for sensor firings during the second time period if the activity pattern frame of reference is based on the total time for sensor firings during the first time period;
comparing the computed activity pattern value with the activity pattern frame of reference and the defined statistical parameter threshold to determine whether the computed activity pattern value deviates from the activity pattern frame of reference by more than the defined number of the standard deviations;
generating an alert based on a determination that the computed activity pattern value deviates from the activity pattern frame of reference by more than the defined number of standard deviations;
receiving a feedback response to the alert, the feedback response including feedback regarding clinical relevance of the alert; and
adjusting the defined number of the standard deviations for the statistical parameter threshold to a different defined number of the standard deviations based on the feedback response to the alert.

US Pat. No. 10,188,290

SYSTEM AND METHOD FOR TRACKING MOTION

StereoVision Imaging, Inc...

1. A system for determining motion of a target, the system comprising:a video imaging system configured to capture a plurality of images of the target;
a lidar system configured to generate a range measurement and a Doppler velocity measurement for each of a plurality of points on the target; and
a processor configured to:
determine, from the plurality of images of the target, at least one first aspect of motion of the target based on the plurality of images of the target,
determine, from the range measurement and the Doppler velocity measurement for each of the plurality of points on the target, at least one second aspect of motion of the target, wherein the at least one first aspect of motion of the target is orthogonal to the at least one second aspect of motion of the target, and
combine the at least one first aspect of motion of the target determined from the plurality of images of the target and the at least one second aspect of motion of the target determined from the range measurement and the Doppler velocity measurement for each of the plurality of points on the target to determine the motion of the target.

US Pat. No. 10,188,288

INFORMATION SYSTEM AND METHOD FOR PROVIDING INFORMATION USING A HOLOGRAPHIC ELEMENT

Apple Inc., Cupertino, C...

1. A light-based information system, comprising:a first holographic element positioned to refract light, at a first one or more characteristic discrete wavelengths, incident from an environment, wherein the first one or more characteristic discrete wavelengths correspond to a refraction on a first concave side of a first surface constructed according to a curvature of a first rotationally symmetrical ellipsoid;
an optical scanning device positioned to detect the refracted light from the first holographic element and to generate a perceived field of vision;
an optical projection device positioned to receive the perceived field of vision and to produce a modified perceived field of vision; and
a second holographic element positioned to refract the modified perceived field of vision, at a second one or more characteristic discrete wavelengths, so as to generate an optical output, wherein the second one or more characteristic discrete wavelengths correspond to a refraction on a second concave side of a second surface constructed according to a curvature of a second rotationally symmetrical ellipsoid.

US Pat. No. 10,188,286

TOMOGRAPHIC IMAGE CAPTURING DEVICE

KOWA COMPANY, LTD., (JP)...

1. A tomographic image capturing device comprising:a tomographic image capturing means that scans measurement light on a subject's eye fundus to capture tomographic images of the subject's eye fundus; and
an image processing means that compresses a picture of the captured tomographic images in a scan direction to generate a new tomographic picture.

US Pat. No. 10,188,273

BIOLOGICAL NAVIGATION DEVICE

LOMA VISTA MEDICAL, INC.,...

1. A device for navigation through a biological anatomy, the device comprising:a tube configured to be advanced through the biological anatomy, the tube having a tube lumen therein;
a steering portion configured to bend to orient the device, said steering portion comprising an actuator for controlling the steering portion;
a reciprocating portion comprising a first tubular reciprocating element and a second tubular reciprocating element, the first tubular reciprocating element attached to a distal end of the steering portion, the second tubular reciprocating element mounted to and surrounding the first tubular reciprocating element, wherein an entirety of the second tubular reciprocating element is configured to longitudinally translate relative to the first tubular reciprocating element, wherein the second tubular reciprocating element remains coaxial with the first tubular reciprocating element during longitudinal translation of the second tubular reciprocating element relative to the first reciprocating element;
a visualization element for visualizing the biological anatomy; and
a distal tip at a distal end of the second tubular reciprocating element having a tip lumen therein continuous with the tube lumen, the tip lumen configured to hold the visualization element therein;
wherein longitudinal translation of the second tubular reciprocating element causes corresponding longitudinal translation of the visualization element held within the tip lumen of the distal tip.

US Pat. No. 10,188,269

MANUFACTURING METHOD FOR IMAGE PICKUP UNIT AND IMAGE PICKUP UNIT

OLYMPUS CORPORATION, Tok...

1. A method comprising:bonding lens wafers comprising optical components to form a lens unit wafer comprising lens units;
bonding a bending optical element wafer comprising bending optical elements to a first surface of the lens unit wafer to form an optical unit wafer such that the bending optical elements are respectively opposed to the lens units to arrange respective inclined planes of the bending optical elements to be inclined relative to the first surface of the lens unit wafer to refract light beams emitted from the lens units towards respective emission surfaces of the bending optical elements;
separating and individualizing the optical unit wafer for each of the lens units and the bending optical elements to manufacture optical units; and
respectively bonding solid-state image pickup devices to the emission surfaces of the bending optical elements of the optical units.

US Pat. No. 10,188,268

ENDOSCOPE

OLYMPUS CORPORATION, Tok...

1. An endoscope comprising:an insertion portion configured to be inserted into a subject;
a distal end portion disposed at a distal end of the insertion portion and including a housing part having a recess and an opening part that opens toward a distal end direction;
a tube having a tubular shape disposed in the insertion portion and formed of a flexible material;
an exit member fitted to a peripheral edge of the opening part in a liquid-tight manner in the housing part of the distal end portion, including an opening through which a treatment instrument protrudes, and forming a treatment instrument guiding-out path into which the treatment instrument is inserted when the opening is connected so as to communicate with the tube; and
an adjusting portion configured to change a protruding direction of the treatment instrument protruding from the opening of the exit member by changing a tilt angle of the treatment instrument guiding-out path by bending the tube connected to the opening of the exit member
wherein the adjusting portion comprises: a transferring portion made of a bar member, the bar member including a rotation shaft rotatable supported in the distal end portion and a contact portion that is in contact with an outer surface of the tube; and
an operation wire one end of which is connected between the rotation shaft and the contact portion of the bar member, the operation wire being configured to rotate the transferring portion by another end of the operation wire being moved forward and backward, to bend the tube and change the tilt angle of the treatment instrument guiding-out path.

US Pat. No. 10,188,262

DISHWASHER COMPRISING A SORPTION DRYING MACHINE

1. A dishwasher, comprising:a washing container;
an air-guiding channel to generate an air flow;
a sorption drying system to dry items to be washed, the sorption drying system having a sorption container with reversibly dehydratable sorption material, the sorption container connected to the washing container by the air-guiding channel; and
a heater disposed in the sorption container and arranged upstream of the reversibly dehydratable sorption material for desorption of the reversibly dehydratable sorption material,
wherein the air-guiding channel includes an inlet connecting piece connected to the sorption container and which diverts incoming air flow from an inflow direction by between 45° to 135° into a through-flow direction through the heater and the reversibly dehydratable sorption material,
wherein the through-flow direction through the heater and through the reversibly dehydratable sorption material is the same direction, such that the through-flow direction runs from a bottom portion to a top portion of the sorption container, and
wherein the dishwasher is configured to control a ratio of a heat output of the heater and an air volume flow of the air flow which flows through the sorption material to be between 100 W sec/l and 1250 W sec/l.

US Pat. No. 10,188,259

PUMP AND DISHWASHER PROVIDED WITH PUMP

LG ELECTRONICS INC., Seo...

1. A dishwasher comprising:a tub providing a washing space;
a rack located inside the tub and configured to receive washing targets;
a spray arm configured to spray water to the rack;
a sump in which the water is received;
an inlet chamber providing a space into which the water from the sump is supplied;
an outlet chamber connected with the inlet chamber and configured to guide the water from the inlet chamber to the spray arm;
an impeller located in the outlet chamber and configured to move the water to the spray arm;
a first housing fixed on the outlet chamber;
a rotor rotatably provided inside the first housing;
a rotation shaft passing through the outlet chamber, the rotation shaft connecting the rotor with the impeller;
a magnetic field formation unit surrounding the first housing, the magnetic field formation unit configured to produce a rotating magnetic field to rotate the rotor;
a friction bearing passing through the outlet chamber, the friction bearing rotatably supporting the rotation shaft;
an outlet path connecting the inside of the first housing with the outlet chamber;
a spacer through which the rotation shaft passes arranged to maintain a spacing between the rotor and the friction bearing; and
a guide path provided in the spacer for guiding water supplied into a space formed between the rotation shaft and the friction bearing to a contact surface between the spacer and the friction bearing,
wherein a rotational axis of the rotation shaft is perpendicular to a horizontal surface to prevent water from contacting the rotor.

US Pat. No. 10,188,244

DISPENSER AND METHOD OF REPLENISHING A DISPENSER

1. A dispenser for dispensing a sheet of web material from a stack of folded web material, the dispenser comprising:a web material storage section arranged to hold and support the stack of folded web material, in a generally vertical direction during dispensing of the web material;
the web material storage section comprising
an upper end portion from which the web material is arranged to be lead for dispensing thereof,
a lower end portion, opposite to the upper end portion and being arranged to support the stack of folded web material in said generally vertical direction, at least when the dispenser is in said dispensing position,
said upper end portion and lower end portion being arranged in a fixed spatial relationship;
wherein:
the lower end portion of the web material storage section comprises
a loading opening and
a supporting arrangement, arranged to be movable between
a support position wherein the supporting arrangement extends at least partially over said loading opening enabling said support of the stack of folded web material, and
an insert position, wherein the supporting arrangement is at least partially removed from the loading opening;
wherein said supporting arrangement is arranged to be movable from said support position to said insert position by pushing a stack to be introduced in the loading opening towards the supporting arrangement in a direction towards the upper end portion of the web material storage section.

US Pat. No. 10,188,241

DISPENSER ASSEMBLY

Vi-Jon, Inc., St. Louis,...

1. A dispenser assembly for dispensing a product, the dispenser assembly comprising:a bottle configured to store the product, the bottle comprising a back wall, the back wall comprising:
a substantially flat surface;
an angled surface extending outwards from the flat surface; and
an extension portion extending outwards from the flat surface, the extension portion having a width less than a width of the flat surface; and
a battery holder, the battery holder comprising:
a housing; and
a plurality of batteries contained in the housing,
wherein the battery holder is positioned adjacent the flat surface of the back wall of the bottle and below the angled surface of the back wall; and
wherein the housing of the battery holder comprises an intermediate wall separating laterally adjacent batteries, the intermediate wall comprising an angled portion that accommodates the extension portion of the bottle back wall.

US Pat. No. 10,188,232

DECORATIVE ARTICLE WITH RECEIVING MEMBER

Hee Kyung Lee, Suwon-si ...

1. A decorative article comprising:a base plate having at least one hanging elongate slot defined therein; and
a receiving member including a single first plate, at least two second plates, and a hanger, wherein the first plate is parallel to the base plate, each of the at least two second plates is non-parallel to the base plate and is coupled to the first plate to define an inner space and a top opening in the receiving member, and the hanger protrudes from the first plate along a top edge of the first plate, wherein the hanger is fitted into the hanging elongate slot to secure the receiving member to the base plate,
wherein the base plate has at least one decorative elongate slot defined therein,
wherein the at least one decorative elongate slot is adjacent to the at least one hanging elongate slot in a non-contacting manner to form a polygonal shape together with the at least one hanging elongate slot,
wherein the first plate falls within the polygonal shape defined by the least one hanging elongate slot and the at least one decorative elongate slot, and sides of the first plate are configured to correspond to the least one hanging elongate slot and the at least one decorative elongate slot such that the first plate has a geometrical shape substantially identical with the polygonal shape.

US Pat. No. 10,188,228

PILLOW WITH GUSSET OF OPEN CELL CONSTRUCTION

Bedgear, LLC, Farmingdal...

1. A pillow comprising:a cover having opposing first and second panels and a gusset joining the first panel with the second panel;
an inner cover disposed within the cover; and
a fill material disposed within the cover,
wherein the gusset has a first porosity, the panels each have a second porosity and the inner cover has a third porosity, the second porosity being different than the first porosity and the third porosity, and the third porosity being different than the first porosity, the second porosity being greater than the third porosity.

US Pat. No. 10,188,215

LOUNGE ASSEMBLIES FOR SUPPORTING PORTABLE ELECTRONIC DEVICES

Steelcase Inc., Grand Ra...

20. A hood assembly for supporting a portable electronic device having a display screen in a viewable position, the assembly comprising:a hood coupled to a base, the hood including a wall structure that includes an internal surface that forms a substantially downwardly opening cavity, the cavity including a front portion and a rear portion, the cavity opening circumscribed by a lower edge that has a front edge portion adjacent the front portion of the cavity;
a support device supported within the hood and adjacent the front edge portion, the support device configured to receive and support the portable electronic device with the device display screen disposed at an oblique angle to the internal surface such that the display screen is facing and in a line of sight of a user within the hood and blocked from a line of sight from outside of the hood when the hood is in a viewing position; and
a communications device provided in at least one of the hood and the base, and wherein the communications device is configured to communicate with the portable electronic device
wherein the communications device comprises a wireless transceiver coupled within the hood, the transceiver having a sensing field restricted to the space of the cavity.

US Pat. No. 10,188,209

SECURING DEVICE FOR DETACHABLY SECURING A FRONT PANEL ON A DRAWER

Julius Blum GmbH, Hoechs...

1. A securing device for releasably securing a front panel to a drawer, comprising:a furniture fitting to be pre-fitted to the front panel;
a catching device to be connected to the drawer, the catching device configured such that, upon insertion of the furniture fitting, the catching device automatically holds the furniture fitting, and the catching device having a moveable catching element, and
a locking device configured to prevent unintentional release of the furniture fitting from the securing device,
wherein the locking device has a moveable locking element separate from the catching element and configured to bear against the pre-fittable furniture fitting in a locked position, the catching element and the separate locking element being motionally coupled, and
wherein the securing device further comprises an adjusting element fixed to the catching element to couple the motion of the catching element to the motion of the locking element, the adjusting element engaging into an opening in the locking element.

US Pat. No. 10,188,208

DRIVE MECHANISM FOR A MOVABLE FURNITURE PART

Julius Blum GmbH, Hoechs...

1. A drive device for moving a movable furniture part, the drive device comprising:an entrainment member configured to be mounted to one of a furniture carcass and the movable furniture part;
a force-actuated drive element configured to be mounted to the other one of the furniture carcass and the movable furniture part so as to be movable in a drive movement direction, the drive element having a drive limit stop by which the entrainment member is moved during a drive movement in the drive movement direction, and the drive element including a passing ramp on a side facing away from the drive limit stop, the passing ramp being configured to allow the entrainment member to pass over the drive element in the drive movement direction; and
a catch lever for catching the entrainment member, the catch lever facing towards the drive limit stop such that the entrainment member is configured to be positioned between the drive limit stop and the catch lever during the drive movement in the drive movement direction, and the catch lever being pivotably supported on a base part of the drive element such that a distance between the catch lever and the drive limit stop changes as the catch lever is pivoted.

US Pat. No. 10,188,206

CONVERTIBLE FURNITURE UNIT, SLAT FOR USE IN FORMING A FURNITURE UNIT AND METHOD OF USING A CONVERTIBLE FURNITURE UNIT

DESIGNARIUM INC., Laval ...

1. A convertible furniture unit comprising a hinge member pivotally linking first and second furniture portions to allow said first and second furniture portions to relatively pivot relative to each other to adopt a number of different angular relative positions, and a locking mechanism to releasably lock said first and second furniture portions in a given angular relative position, said first and second furniture portions each comprising a number of slats that are intermeshed with and are slidable between the slats of the other one of said first and second furniture portions, each said slat comprising a hinge portion pivotally attached to said hinge member, an arm extending away from said hinge portion and a free extremity opposite said hinge portion, said first and second furniture portions being capable of adopting at least:a first position wherein said arms of said slats of said first furniture portion extend away from said hinge member and between two adjacent said arms of said slats of said second furniture portion; and
a second position in which said arms of said slats of said first furniture portion extend away from said hinge member and away from said arms of said slats of said second furniture portion without extending between two adjacent said arms of said slats of said second furniture portion;wherein said first and second positions of said first and second furniture portions are both operable for use of said furniture unit by a user.

US Pat. No. 10,188,204

DESK WITH STABILITY FEATURE

Argosy Console, Inc., El...

1. A desk comprising:a desktop defining a height configured to be adjusted between a lower position and an upper position;
a leg comprising an attachment portion and a foot portion, the attachment portion of the leg secured to the desktop and extending away from the desktop, the attachment portion of the leg configured to move with respect to the foot portion of the leg along an axis of the leg to adjust a height of the desktop about and between the lower position and the upper position, the foot portion of the leg defining a bottom end of the desk; and
a gas spring extending from the leg to the desktop, the gas spring angled with respect to the leg by an angle of at least 5 degrees and with respect to the desktop by an angle of at least 5 degrees, the gas spring configured to dampen movement of the desk when a force comprising a horizontal component is applied to an edge of the desktop when the desktop is in the upper position.

US Pat. No. 10,188,184

FOLDING SUITCASE

VOYLUX COMPANY LIMITED, ...

1. A folding suitcase, comprising:a back case component;
a front lid component;
a peripheral side wall component with two sides which are opposite to each other, an edge of the back case component and an edge of the front lid component being connected to the two sides of the peripheral side wall component respectively, thereby forming an accommodating space which is for being covered selectively, the peripheral side wall component having a plurality of first sidewall parts, a plurality of second sidewall parts and a plurality of bending parts connected to the plurality of first sidewall parts and the plurality of second sidewall parts, and the plurality of bending parts being bendable to allow the plurality of first sidewall parts and the plurality of second sidewall parts to be folded oppositely or erected on the back case component, each of the plurality of bending parts comprising a bending section and a link-up section, the plurality of bending sections being connected to the plurality of first sidewall parts, and the link-up section of each of the plurality of bending parts being connected to the plurality of second sidewall parts;
at least one fold-resisting component, the at least one fold-resisting component being elastic and comprising a combined part and an extension part which are connected to each other, the combined part being disposed at one of the plurality of first sidewall parts;
two bendable fixing components, each of the two bendable fixing component having a fixing section and a suspension section which are connected with each other, the two fixing sections being located on two of the plurality of second sidewall parts of the peripheral side wall component, respectively, the two suspension sections being disposed across the bending sections of the bending parts, respectively;
two restoring components, located at an inner side of the peripheral side wall component by the two bendable fixing components respectively with each of the restoring components being disposed across at least one bending part, the two restoring components being elastic, and an elasticity of the at least one fold-resisting component being greater than an elasticity of the two restoring components;
an elastic component, the two suspension sections being connected to two ends of the elastic component, respectively;
a first combination component, disposed at the bending part close to the first sidewall part at which the combined part is disposed; and
a second combination component, disposed at the extension part of the at least one fold-resisting component, the extension part of the at least one fold-resisting component being detachably disposed at the link-up section by the first combination component and the second combination component, such that the fold-resisting component is disposed across the bending section, the first combination component and the second combination component being two attached components with hooks and loops and the first combination component being detachably combined with the second combination component.

US Pat. No. 10,188,159

APPARATUS, SYSTEM, AND METHOD FOR REDUCING HEAD OR NECK TRAUMA

ARMOUR TECHNOLOGIES, INC....

1. An apparatus for reducing trauma in the head or neck of a living being caused by acceleration of the head relative to the torso of the living being within a range of motion, the apparatus comprising:a support configured to engage at least one of the head, neck, and shoulder of the living being; and
a physiological damper including at least one electrode associated with the support and an actuator coupled to actuate the electrode, wherein the electrode is positioned to stimulate a muscle of the living being to (1) increase resistance to the motion provided by the muscle in response to a sensed position, speed or acceleration of the head of the living being, or (2) strengthen the muscle of the living being to counteract a force applied to the head of the living being.

US Pat. No. 10,188,138

SMOKING ARTICLE WITH MANUALLY RELEASABLE ODORANT

Philip Morris USA Inc., ...

1. An article comprising:a tobacco portion;
a filter connected axially aligned with and connected to the tobacco portion;
a tipping paper circumscribing at least a portion of the tobacco portion and at least a portion of the filter;
a first band on at least a portion of the tipping paper, the first band including,
a first layer of a first material over the tipping paper, and
a first plurality of microcapsules between the tipping paper and the first layer of material, the plurality of microcapsules being frangible; and
a second band on a second portion of the tipping paper, the second band including,
a second layer of a second material, and
a second plurality of microcapsules between the tipping paper and the second layer, the second plurality of microcapsules being frangible.

US Pat. No. 10,188,120

MULTIPLE DRAWER SMOKER

LANDMANN USA, Fairburn, ...

1. A smoking apparatus comprising a cabinet having side and rear walls, an upper smoking chamber with a front access door and a lower section having at least two independently operable drawers, one of said drawers disposed above the other and each of said drawers having a front panel with right and left side panels forming an enclosure, a handle attached to each of said front panels, said handles located outside said cabinet, one of said drawers configured to hold a flavoring material and the second drawer configured to hold a liquid, a support surface for each of said drawers secured to said side walls of said lower section, whereby said drawers can be moved into and out of said cabinet using said handles, and a heating element disposed within said cabinet.

US Pat. No. 10,188,107

SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES

HEINRICH HEINE UNIVERSITA...

1. A method of using at least one compound, a salt or solvate thereof as a C4 plant selective herbicide, comprising applying said compound, salt or solvate to a plant, wherein binding of said compound to the malate binding site of aphosphoenolpyruvate carboxylase from a C3 plant is inhibited, and wherein said compound has a structure according toformula (I)
wherein A iswherein R6, R7, R8, R9 and R10 are, independently of each other, selected from the group consisting of H, OH, carboxylic acid, ester, alkyl, alkoxy and halogen, or wherein two residues in ortho position to each other form a heterocyclic ring using —O—CH2—O— or —O—CH2—CH2—O, andB is
wherein R11, R12, R13, R14 and R15 are, independently of each other, selected from the group consisting of H, OH, carboxylic acid, ester, alkyl, alkoxy and halogen, or wherein two residues in ortho position to each other form a heterocyclic ring using —O—CH2—O— or —O—CH2—CH2—O—,
and wherein R1, R2, R3, R4 and R5 are, independently of each other H or an alkyl group,
and wherein integer i is 0 or 1,
and the bond (a) is a single or double bond,
and wherein in case (a) is a double bond, n is 0 and X is O or S, and wherein in case (a) is a single bond n is 1, and X is H or an alkyl group,
and wherein the bond (b) is a single or double bond, and wherein in case (b) is a double bond, m and p are 0, and wherein in case (b) is a single bond m and p are both 1,
and wherein said compound being capable of binding to the malate binding site comprised by a phosphoenolpyruvate carboxylase from a C4 plant, thereby inhibiting said phosphoenolpyruvate carboxylase.

US Pat. No. 10,188,091

PORTABLE LIGHT AND INSECT EXTERMINATION DEVICE

alliance sports group, I....

1. A handheld lighting apparatus, comprising:a top housing coupled to a first light source and an electrical grid configured to distribute a quantity of electricity to an object that contacts adjacent portions of the grid, the top housing being slidably mounted to a bottom housing having a cavity therein, the cavity being configured to receive the electrical grid assembly therein,
wherein the first light source emits light ranging from about 400 nm to about 720 nm in a first mode and light ranging from about 315 nm to about 400 nm in a second mode;
an enclosure disposed about the electrical grid assembly configured to permit passage of insects through portions of the enclosure;
a second light source disposed about the bottom housing configured to propagate light in a direction that is parallel to a longitudinal direction of the lighting apparatus;
a power source coupled to the first and second light source and the electric grid; and
a programmable logic control system coupled to a switch and the power source, the control system configured to operate the first light source such that light propagated from one or more LEDs of the first light source ranging from about 315 nm to about 400 nm is pulse width modulated at a rate greater than about 20 KHz while light propagated from one or more LEDs of the first light source ranging from about 400 nm to about 720 nm is not pulse width modulated or is pulse width modulated at a rate below 2 KHz.

US Pat. No. 10,188,088

FISH STRIKE INDICATING APPARATUS, SYSTEM AND METHOD FOR USE WITH AN ICE FISHING TIP-UP

Deep Freeze, LLC, Steven...

1. A fish strike indicating apparatus comprising:an enclosure configured to attach to an ice fishing tip-up flagpole, the enclosure comprising
a cylindrical mounting channel extending longitudinally along a first side of the enclosure, the cylindrical mounting channel adapted to securely receive the flagpole;
a transmitting apparatus disposed inside of the enclosure, wherein the transmitting apparatus is configured to transmit a wireless signal indicative of a fish strike to a mobile device; and
a receiving apparatus disposed inside of the enclosure, wherein the receiving apparatus is configured to receive a wireless signal from the mobile device.

US Pat. No. 10,188,086

INSECT PRODUCTION SYSTEMS AND METHODS

1. A method to separate crickets from a cricket and gas mixture, the method includes:(a) providing:
a separator having an input and an output, the input is configured to accept a cricket and gas mixture, the separator is configured to separate crickets from the cricket and gas mixture and output a cricket-depleted gas stream via said output, the cricket-depleted gas stream has a reduced amount of crickets relative to the cricket and gas mixture; and
(b) separating crickets from the cricket and gas mixture to form a cricket-depleted gas stream that has a reduced amount of crickets relative to the cricket and gas mixture.

US Pat. No. 10,188,085

SYSTEM AND METHODOLOGY FOR CULTURING COCHINEAL INSECTS ON AN ARTIFICIAL MEDIUM

SciConsult, Inc., Fort W...

1. A self-supporting mass, comprising:an artificial culture medium which contains a plant additive and which has been inoculated with a plurality of insects selected from the group consisting of the genus Dactylopius;
wherein said artificial culture medium further comprises a three-dimensional matrix.

US Pat. No. 10,188,084

INSECT PRODUCTION SYSTEMS AND METHODS

1. A insect breeding system comprising:a roller positioned along a conveyor path;
a breeding material positioned on the roller;
a water source positioned on the conveyor path to apply water to the breeding material;
a motor coupled to the roller to drive the roller and rotate the roller and move the breeding material along the conveyor path and past the water source; and
a sensor configured to analyze at least a portion of the breeding material;
wherein:
the sensor is selected from the group consisting of an optical sensor, a digital camera, a motion sensor, an active infrared sensor, a passive infrared sensor, a microwave motion sensor, a continuous wave radar motion sensor, a vibration motion sensor, an infrared (IR) sensor, an ultrasonic sensor, a proximity sensor, a touch sensor, a mass sensor, a laser sensor, and combinations thereof.

US Pat. No. 10,188,077

HANG-ON NATURAL WATER DRINKING SYSTEM

Ying Yeeh Enterprise Co.,...

1. A hang-on natural water drinking system, provided in form of a hang-on drinking system adapted to effectuate a natural water state, the hang-on drinking system comprising:a holder having a pipe segment;
a water-holding unit for holding drinking water and laterally provided with a connecting segment for drawing water off the water-holding unit, allowing the pipe segment to fit around the connecting segment; and
a drinking unit serving pets and comprising a basic drinking portion, a supporting portion, and a diverting portion, the basic drinking portion having an end extending to form a guide trough, the guide trough abutting against the connecting segment from below to guide water to the basic drinking portion, allowing water to go from an end of a submerged motor to the diverting portion coupled to the basic drinking portion, allowing the water in the diverting portion to flow across at least one blocking region defined at the diverting portion in a manner to enter a turbulent white-water drinking state, wherein the water not only enters the basic drinking portion to serve the pets, but is also driven by the submerged motor coupled to the basic drinking portion to move upward and get introduced into the diverting portion so that the water from the water-holding unit circulates through the drinking unit continuously.

US Pat. No. 10,188,048

SYSTEMS AND METHODS FOR MONITORING MOVEMENT OF DISEASE FIELD

BE SEEN BE SAFE LTD., To...

1. A method for monitoring movement of disease across agricultural areas of interest comprising:displaying, on a map of an application of a first device, at least one virtual zone corresponding to an agricultural geographic area of interest,
the at least one virtual zone defined by at least one geofence,
each virtual zone associated with a level of risk that indicates a likelihood of an outbreak of a disease detrimental to agriculture within the agricultural area of interest,
each virtual zone configured to receive access notification information from each geofence when tracked devices enter an area defined by that geofence,
the access information including the level of risk associated with the tracked devices, and
the level of risk associated with the virtual zone comprising a level of risk associated with the tracked devices that have entered an area defined by the virtual zone within a period of time associated with the disease; and
receiving an alert message associated with a level of risk when the first device is in proximity to a virtual zone associated with that level of risk, the alert message received prior to the first device entering the virtual zone.

US Pat. No. 10,188,045

APPARATUS, SYSTEM AND METHOD FOR ERADICATING SOIL-BORNE PESTS USING VARIABLE CONTROLLED ELECTRIC CURRENT

David Michael Flagler, S...

1. An apparatus for introducing electricity into soil to eradicate soil-borne pests, said apparatus comprising:a frame having a plurality of frame members;
a leading row supported by said frame, said leading row having a plurality of downwardly pointing ripper shanks, each of said ripper shanks configured to cut a path through the soil;
a trailing row supported by said frame behind said leading row, said trailing row having a plurality of downwardly disposed stinger shanks that each comprise at least one electrically conductive exterior surface, each of said stinger shanks being aligned with one of said ripper shanks so as to define a plurality of shank pairs therewith and to move through said path cut by said corresponding ripper shank;
a source of electricity electrically connected to each of said stinger shanks so as to transmit a quantity of electricity thereto;
a voltage controller electrically connected to said source of electricity and configured to select said quantity of electricity to be transmitted to each of said stinger shanks based on the condition of the soil; and
a probe row supported by said frame between said leading row and said trailing row, said probe row having a soil probe configured to move through one of said paths formed by said leading row, read the condition of the soil in said path and transmit a reading signal to said voltage controller, said voltage controller further configured to receive and process said reading signal to automatically determine said quantity of electricity required to be transmitted to each of said stinger shanks to effectively and efficiently eradicate the pests by continuously discharging electricity from said source of electricity into the soil from said stinger shanks as said stinger shanks move through the soil.

US Pat. No. 10,188,042

ROUND BALER WITH BALE WRAPPER

1. A round baler with a bale wrapper wherein the bale wrapper comprises:a bale wrapping unit which rotates about a vertical axis of rotation and has rotation arms which extend parallel to the axis of rotation and which support reels of wrapping material guided inside an action region of the bale wrapping unit extending transversely and longitudinally relative to the axis of rotation, wherein a delimiting rod linkage is arranged on the round baler or on the bale wrapper and extends at the back of the round baler and is capable of pivoting from an upper position located above the bale wrapping unit into a lower position located around the rear and sides of the bale wrapping unit, the delimiting rod linkage being narrower in the transverse direction of the round baler when in the upper position.

US Pat. No. 10,188,035

LOAD-BASED YIELD SENSOR

Intelligent Agricultural ...

5. A system for estimating the weight of a crop harvested in a harvesting machine including a grain elevator having a conveyor belt with upper and lower ends positioned within the harvesting machine and an on-board processor with a non-volatile memory, said processor controlling crop harvesting and weighing operations, which system comprises:first and second weight sensors operably connected at first and second sides of said conveyor belt upper end at approximately equal elevations;
each said weight sensor configured for providing an output corresponding to a portion of the conveyor belt weight on a respective conveyor belt upper end first or second side;
wherein said weight sensors comprise potentiometers configured for providing output corresponding to deflection of said conveyor belt upper end sides;
each said weight sensor output comprising an input to said processor;
said processor configured for processing data received from said weight sensors;
said processor configured for initializing with an empty conveyor belt weight;
said elevator configured for lifting said harvested crop within said harvesting machine;
each said weight sensor configured for providing an output to said processor comprising a loaded conveyor belt weight while said conveyor belt is lifting said harvested crop;
said processor configured for subtracting said empty conveyor belt weight from said loaded conveyor belt weight to determine a weight of harvested crop on each side of said conveyor belt;
said processor configured for providing output corresponding to said harvested crop weight;
said processor configured for adjusting crop harvesting parameters to compensate for asymmetrical weight conditions on said conveyor belt; and
wherein said crop harvesting parameters are selected from the group consisting of: harvesting machine speed; direction; crop quality; engine RPM; sieve spacing; harvester machine fan-rotor speed; and combinations thereof.
US Pat. No. 10,189,924

HIGH DENSITY ROTOMOLDING RESIN

NOVA Chemicals (Internati...

1. A polyethylene resin comprising from 0.7 to 1.2 weight % of 1-octene and the balance ethylene, having a density from 0.948 to 0.953 g/cc, a melt index determined according to ASTM1238 under a load of 2.16 kg at a temperature of 190° C. (I2) from 1.0 to 1.5 g/10 minutes; a melt index determined according to ASTM1238 under a load of 21.6 kg at a temperature of 190° C. (I21) from 32 to 55 g/10 minutes; a weight average molecular weight (Mw) determined by gel permeation chromatography from 95,000 to 120,000; a number average molecular weight determined by gel permeation chromatography (GPC) from 20,000 to 40,000; a z average molecular weight (Mz) from 240,000 to 360,000; an Mw/Mn from 2.7 to 4.3; an Mz/Mw from 2.5 to 3.5; and having a CBDI (50) from 80 to 95, the molecular weight distribution determined by GPC of said polymer being deconvoluted into at least two components comprising:from 20 to 40 weight % of a first component having a calculated weight average molecular weight (Mw) being from 200,000 to 250,000; a calculated number average molecular weight from 90,000 to 140,000; a z average molecular weight 390,000 to 520,000 and an estimated density from 0.921 to 0.930 g/cc;
from 60 to 80 weight % of a second component having a calculated weight average molecular weight (Mw) being from 20,000 to 57,000; a calculated number average molecular weight (Mn) from 10,000 to 27,000; a z average molecular weight from 30,000 to 72,000 and an estimated density from 0.948 to 0.953 g/cc, provided that the difference in calculated density between component two and component one is less than 0.030 g/cc.
US Pat. No. 10,190,180

COMPOSITIONS AND METHODS FOR AMPLIFYING AND CHARACTERIZING HCV NUCLEIC ACID

GEN-PROBE INCORPORATED, ...

1. A method for determining at least partial genotype information for hepatitis C virus type la (HCV-la) in a sample, the method comprising:(1) contacting a sample, said sample suspected of containing HCV-la, with
at least two amplification oligomers for amplifying at least one target region of an HCV-la target nucleic acid, wherein said at least one HCV-la target region is selected from the group consisting of
(a) a first target region comprising nucleotide positions 8522 to 9372 of SEQ ID NO:155 or the complement thereof, wherein if the first target region is amplified, then the at least two amplification oligomers comprise (i) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs:65, 43, and 34; and (ii) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs:69, 38, and 41;
(b) a second target region comprising nucleotide positions 7788 to 8838 of SEQ ID NO:155 or the complement thereof, wherein if the second target region is amplified, then the at least two amplification oligomers comprise (i) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 57, 63, and 28; and (ii) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 40, 35, and 42;
(c) a third target region comprising nucleotide positions 6966 to 7970 of SEQ ID NO:155 or the complement thereof, wherein if the third target region is amplified, then the at least two amplification oligomers comprise (i) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 60, 58, and 36; and (ii) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 31, 73, and 62;
(d) a fourth target region comprising nucleotide positions 6076 to 7117 of SEQ ID NO:155 or the complement thereof, wherein if the fourth target region is amplified, then the at least two amplification oligomers comprise (i) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 55, 70, and 29; and (ii) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs:46, 45, and 61;
(e) a fifth target region comprising nucleotide positions 5094 to 6304 of SEQ ID NO:155 or the complement thereof, wherein if the fifth target region is amplified, then the at least two amplification oligomers comprise (i) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 39, 44, and 68; and (ii) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 47, 51, and 59;
(f) a sixth target region comprising nucleotide positions 4258 to 5297 of SEQ ID NO:155 or the complement thereof, wherein if the sixth target region is amplified, then the at least two amplification oligomers comprise (i) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 52, 49, and 72; and (ii) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 37, 75, and 53; and
(g) a seventh target region comprising nucleotide positions 3434 to 4482 of SEQ ID NO:155 or the complement thereof, wherein if the seventh target region is amplified, then the at least two amplification oligomers comprise (i) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 77, 79, and 81; and (ii) at least one oligomer comprising a target-hybridizing sequence comprising a nucleotide sequence selected from SEQ ID NOs: 78, 80, and 71;
(2) performing at least one in vitro nucleic acid amplification reaction, wherein any HCV-la target nucleic acid present in said sample is used as a template for generating at least one amplification product corresponding to at least one of the first through seventh target regions; and
(3) detecting the nucleobase at one or more nucleotide positions within the at least one amplification product, thereby determining at least partial genotype information for the HCV-la in said sample.
US Pat. No. 10,188,135

METHOD FOR INDUCING SATIETY

Stokley-Van Camp, Inc., ...

1. A method comprising providing to a consumer a food product comprising, per a serving size of 40-80 grams dry weight or 177-354 mL liquid, protein and leucine, said protein being present in an amount of less than about 13.5 grams of total protein, and said leucine being present in an amount of between about 1.0 to about 3.5 grams of total leucine, said total leucine provided only by a combination of the total protein and a leucine-bound peptide composition, said total protein comprising protein from said leucine-bound peptide composition and one or more protein sources within the food product, said food product inducing satiety in the consumer.
US Pat. No. 10,188,647

COMBINATION THERAPY USING P53 ACTIVATOR AND C-MET INHIBITOR

SAMSUNG ELECTRONICS CO., ...

1. A method of treating cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof:wherein the p53 activator comprises a nutlin compound,
wherein the c-Met inhibitor is an anti c-Met antibody or an antigen-binding fragment thereof that specifically binds to an epitope having a sequence of 5 to 19 consecutive amino acids of SEQ ID NO: 71 including the amino acid sequence EEPSQ (SEQ ID NO: 73), and
wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises
a heavy chain variable region comprising
a polypeptide (CDR-H1) comprising an amino acid sequence of SEQ ID NO: 1,
a polypeptide (CDR-H2) comprising an amino acid sequence of SEQ ID NO: 2, and
a polypeptide (CDR-H3) comprising an amino acid sequence of SEQ ID NO: 3; and
a light chain variable region comprising
a polypeptide (CDR-L1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 10 and 106,
a polypeptide (CDR-L2) comprising an amino acid sequence of SEQ ID NO: 11, and
a polypeptide (CDR-L3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 12, 13, 14, 15, and 16.
US Pat. No. 10,188,137

PROCESS FOR PRODUCING FLAVORANTS AND RELATED MATERIALS

R.J. Reynolds Tobacco Com...

1. A process for making an ester of a fatty acid derived from tobacco seed oil, wherein the ester possesses favorable organoleptic properties, the process comprising contacting a quantity of a composition comprising tobacco seed oil containing C11 triglycerides with (a) a quantity of a composition comprising an alcohol and a quantity of a composition comprising an acid or (b) a quantity of a composition comprising an alcohol and an acid to form a reaction mixture for a period of time sufficient for the formation of a composition comprising a C11 fatty acid ester.
US Pat. No. 10,188,139

ADDITIVES FOR TOBACCO CUT FILLER

Philip Morris USA Inc., ...

1. A method of reducing cytotoxicity and/or mutagenicity in tobacco smoke is provided comprising:applying a solution comprising a mixture of glycerin and a magnesium or calcium salt selected from the group consisting of magnesium nitrate, magnesium chloride, magnesium acetate, magnesium sulfate, calcium nitrate, calcium chloride, calcium acetate and mixtures thereof, onto tobacco cut filler to form a tobacco smoking mixture capable of producing tobacco smoke when burned;
forming a smoking article comprising a wrapper, the tobacco smoking mixture and a filter; and
burning the smoking article to produce tobacco smoke with reduced cytotoxicity and/or mutagenicity;
wherein the glycerin is present in an amount of about 8 to about 13% by weight of the tobacco smoking mixture, and wherein the mixture of glycerin and magnesium or calcium salt is present in an amount effective to reduce the cytotoxicity and/or the mutagenicity of the smoke produced from the tobacco smoking mixture upon burning.
US Pat. No. 10,189,933

METHOD FOR PRODUCING FUNCTIONALIZED THERMOPLASTIC ELASTOMERS

BYK-CHEMIE GMBH, Wesel (...

1. A process for preparing a functionalized thermoplastic elastomer based on particulate graft substrates selected from the group consisting of:(i) olefin block copolymers comprising 80 to 98 mass-% of ethylene- and 2 to 20 mass-% of C3- to C12-olefin units;
(ii) semi-crystalline copolymers of the composition 50 to 98 mass-% of propylene- and 2 to 50 mass-% of ethylene and/or C4- to C12-olefin and/or C4- to C12-diene units, and
(iii) cross-linked styrene/olefin/styrene block copolymers or cross-linked styrene/olefin block copolymers,
wherein in a fluid mixing reactor, is added:
0.1 to 15 mass parts of ?,?-ethylenically unsaturated compounds containing at least one functional monomer or a monomer mixture containing the at least one functional monomer, wherein the at least one functional monomer contains functional groups,
0.01 to 10 mass parts of at least one initiator forming free radicals with a 1-hour half-life temperature (THWZ/1h) between 50 and 200°, and
100 mass parts of the particulate graft substrate;
wherein the unsaturated compounds, the at least one initiator and particulate graft substrate are polymerized at reaction temperatures between 40° C. and the melting or softening temperature of the particulate graft substrate for a reaction time between 10 and 200 min in a solid-fluid phase, wherein a graft product having a grafted functional monomer is produced by such a solid state functionalization, which is used as a starting component for further processing, wherein during further processing:
100 mass parts of the graft product is mixed with: (i) between 0.1 and 60 mass parts of at least one other functional monomer; or (ii) between 0.1 and 60 mass parts of another monomer mixture containing the at least one other functional monomer and between 0.01 and 20 mass parts of at least one other initiator forming free radicals with a 1-hour half-life temperature (THWZ/1h) 80-240° C. producing a mixture; the mixture together with 100 to 4000 mass parts of an unmodified olefin elastomer, are continuously fed into an intake area of a reaction extruder via metering devices,
reactive extrusion from the reactor extruder is carried out at temperatures above melting or softening point of the unmodified olefin elastomer, and
the functionalized thermoplastic elastomer is continuously discharged from the reaction extruder.
US Pat. No. 10,189,934

PREPARATION OF MOLECULARLY IMPRINTED POLYMERS

MIP DIAGNOSTICS LIMITED, ...

1. A process for the preparation of a solution or colloidal suspension of molecularly imprinted polymer (“MIP”) particles comprising the steps of:(a) providing a carrier substance having a template material immobilized on it so the template is exposed at the carrier substance surface;
(b) providing a polymerizable composition in contact with said template;
(c) effecting controlled polymerization of said polymerizable composition in contact with said template by using a method selected from radical polymerization, optionally controlled living radical polymerization (LRP); living anionic polymerization; living cationic polymerization; and controlled polycondensation; iniferter-mediated polymerization, nitroxide-mediated polymerization (NMP), atom-transfer radical polymerization (ATRP) and reversible addition-fragmentation chain-transfer polymerization (RAFT), said polymerization being terminated when MIP particles of less than 1 micrometer have been formed; and
(d) separating said MIP particles from said template by washing and/or eluting thereby forming said solution or colloidal suspension, wherein said carrier substance and said immobilized template can be reused in additional controlled polymerizations of the type set forth in step (c) above.
US Pat. No. 10,190,963

METHODS AND SYSTEMS FOR ASSESSING SAMPLE BEHAVIOR IN A FLOW CYTOMETER

Becton, Dickinson and Com...

1. A method for controlling flow of a flow cytometer sample, the method comprising:flowing the sample comprising a series of particles through the flow cytometer wherein each particle is associated with a signal;
detecting a series of events with a detection system in a first time interval from a stream formed from the flow cytometer;
calculating an expected frequency of events in the first time interval based on a characterizing distribution;
measuring, via the flow cytotneter, an observed frequency of events within a second time interval, wherein the second time interval is within the first time interval;
while particles for the sample are flowing through the flow cytometer, generating an entrainment factor based at least in part on a comparison of the observed frequency to the expected frequency;
determining the entrainment factor indicates a level of sample clumping below a threshold; and
controlling the detection system or the stream formed from the flow cytometer based on the determined entrainment factor while particles for the sample are flowing through the flow cytometer.
US Pat. No. 10,188,662

SOFT LOZENGE COMPOSITIONS

Patheon Softgels, Inc., ...

1. An oral, slow releasing, solid, soft lozenge pharmaceutical composition comprising:(a) about 10% to about 40% by mass of one or more gelatins;
(b) about 1% to about 5% by mass polyethylene oxide having a molecular weight (My) of about 900,000 to about 8,000,000;
(c) about 5% to about 20% by mass of glycerol, sorbitol, mannitol, maltitol, xylitol, or combinations thereof;
(d) about 20% to about 60% by mass of maltitol, xylitol, mannitol, sucralose, aspartame, stevia, or a combination thereof;
(e) about 0.1% to about 5% by mass of one or more organic acids;
(f) 0.005% to about 5% by mass of one or more active pharmaceutical ingredients; and
(g) water;
wherein the composition orally disintegrates within about 30-45 minutes upon oral administration to a subject in need thereof.
US Pat. No. 10,188,664

INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN A HYDROPHOBIC DRUG, A CO-SOLVENT, AND A PRESERVATIVE

JUROX PTY LTD, South Wal...

1. An injectable pharmaceutical composition, in the form of a solution, wherein the injectable pharmaceutical composition complies with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the A criteria for parenterals, comprising:1% w/v to 5% w/v alfaxalone,
8% w/v to 40% w/v 2-hydroxypropyl-?-cyclodextrin,
0.1% w/v to 0.15% w/v chlorocresol,
15% w/v ethanol, and
optionally a phosphate based buffer to provide a pH in a range of 6.0 to 7.5.
US Pat. No. 10,189,178

METHOD FOR PRODUCING WOOD MATERIAL PANELS, IN PARTICULAR OSB WOOD MATERIAL PANELS, AND WOOD MATERIAL PANEL THAT CAN BE PRODUCED IN ACCORDANCE WITH SAID METHOD

SWISS KRONO Tec AG, Luce...

1. A method of producing an OSB wood-base panel, comprising the steps of:a) providing wood strands;
b) applying at least one adhesive system to the wood strands, wherein the adhesive system comprises:
solely a polyurethane adhesive, and
nanoparticles below 500 nm, wherein at least one nanoparticle is modified with at least one compound of general formula (I)
RaSiX(4-a)  (I),
or of general formula (II)
ObXc(OH)dReSiO(4-b-c-d-e)/2  (II),
where
X is H, OH or a hydrolyzable moiety selected from the group consisting of: halogen, alkoxy, carboxyl, amino, monoalkylamino or dialkylamino, aryloxy, acyloxy, alkylcarbonyl,
R is a nonhydrolyzable organic moiety R selected from the group consisting of: substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted cycloalkyl, which may each be interrupted by —O— or —NH—, and
wherein R may include at least one functional group Q selected from a group containing an epoxy, hydroxyl, ether, amino, monoalkylamino, dialkylamino, substituted and unsubstituted anilino, amide, carboxyl, acryloyl, acryloyloxy, methacryloyl, methacryloyloxy, mercapto, cyano, alkoxy, isocyano, aldehyde, alkylcarbonyl, acid anhydride and/or phosphoric acid group,
a is =0, 1, 2, 3,
b, c, d are=0 or 1, and
e is =1, 2, 3;
wherein the adhesive system is admixed to the wood strands in an amount between 1.0 and 2.5 wt % based on the wood strands, and
c) pressing the wood strands admixed with the adhesive system to form the wood-base panel.
US Pat. No. 10,190,204

METHOD FOR COATING LIGHT ALLOY RIMS

BASF SE, Ludwigshafen (D...

1. A method for coating light alloy rims, the method comprising:applying a primer (A) layer directly on a machined light alloy rim blank comprising a cast aluminum alloy, the primer (A) layer comprising at least one radiation-curable coating material having an acid number in accordance with DIN EN ISO 3682 (by potentiometry) of 10 to 120 mg KOH/g;
after applying the primer (A) layer, applying a base coat (B) layer;
after applying the base coat (B) layer, applying a radiation-curable clear coat (C) layer on an outside surface of the light alloy rim, the clear coat (C) layer having a double-bond density of free-radically polymerizable reactive groups per unit mass of coating material of at least 1 mol/kg; and
curing the primer (A) layer, the clear coat (C) layer, and optionally the base coat (B) layer by high-energy radiation selected from the group consisting of light in the wavelength range of 200 nm to 700 nm, an electron beam in the range of 150 keV to 300 keV, and combinations thereof;
wherein:
the primer (A) layer is fully cured with the high-energy radiation and without being further heated after being applied; and
the primer (A) layer, the base coat (B) layer, and the clear coat (C) layer are different from each other.
US Pat. No. 10,188,672

COMPOSITIONS AND METHODS FOR TISSUE REGENERATION

Orbis Health Solutions LL...

1. A composition consisting essentially of tetraethyl orthosilicate and at least one oil selected from the group consisting of jojoba oil, almond oil, cocoa butter, bees wax, and sweet almond oil,wherein the tetraethyl orthosilicate is present in a concentration from 25% to 40% by total weight of the composition, and wherein the composition is presented as a cream or an ointment.
US Pat. No. 10,188,675

NUTRIENT COMPOSITION HAVING LIPID METABOLISM-IMPROVING ACTION

DAICEL CORPORATION, Osak...

1. A method for the nutritional supplementation in a subject in need thereof, comprisingadministering to the subject an effective amount of a water-soluble dietary fiber selected from a cellulose acetate having a total degree of acetyl substitution of 0.4 to 1.1.
US Pat. No. 10,188,679

HUMAN MONOCYTE SUB-POPULATION FOR TREATMENT OF EYE DISEASES AND DISORDERS

Yeda Research and Develop...

1. A method for inhibition of neuronal degeneration, and/or protection of neurons from glutamate toxicity, or promotion of nerve regeneration in the retina or optic nerve, wherein the retina or optic nerve is damaged by a disease, disorder or condition of the eye, said method comprising administering to the eye of an individual in need thereof an effective amount of a monocyte subpopulation of peripheral blood mononuclear cells (PBMCs), said monocyte subpopulation of PBMCs having an amount of having a low relative amount, or substantially devoid, of CD3+ cells, CD19+ cells, CD56+ cells and CD16+ cells each not exceeding 5% of the total number of cells in the monocyte subpopulation.
US Pat. No. 10,188,680

TUMOR LYSATE LOADED PARTICLES

Orbis Health Solutions LL...

1. A composition comprising a yeast cell wall particle and a tumor lysate, wherein about 200 ?g to about 500 ?g tumor lysate is loaded within about 109 yeast cell wall particles.
US Pat. No. 10,189,964

METHODS FOR PREPARING OPEN-CELLED POLYURETHANE FOAMS, SYSTEMS FOR USE THEREIN, AND OPEN-CELLED POLYURETHANE FOAMS PRODUCED THEREBY

COVESTRO LLC, Pittsburgh...

1. A method for preparing an open-celled polyurethane foam, comprising:(a) depositing a polyurethane foam-forming composition comprising a polyisocyanate component and a polyol component into a container having a gas-permeable base, wherein the polyol component comprises:
(i) 20 to 40% by weight, based on the total weight of the polyol component, of a polypropylene oxide-based polyether diol having an OH number in the range of from 450 to 600;
(ii) 30 to 50% by weight, based on the total weight of the polyol component, of a poly(propylene/ethylene oxide) glycerin-initiated polyether triol having an OH number in the range of from 26 to 34; and
(iii) 10 to 30% by weight, based on the total weight of the polyol component, of a polypropylene oxide-based polyether triol having an OH number in the range of from 400 to 550; and
(b) allowing the polyurethane-foam forming composition to form an open-celled polyurethane foam in the container,
wherein the method comprises heating the gas-permeable base, with a heating device comprising a heating pad, matt or plate disposed beneath the gas-permeable base, before, during, and/or after step (a) and continuing the heating during at least a portion of step (b), and
wherein the method is discontinuous.
US Pat. No. 10,188,685

USE OF LACTOBACILLUS PLANTARUM COMPOSITION FOR MANUFACTURING ANTI-FATIGUE PROBIOTIC COMPOSITION TO IMPROVE EXERCISE PERFORMANCE

NATIONAL TAIWAN SPORT UNI...

1. A method for improving exercise performance and reducing muscle fatigue, comprisingadministering a therapeutically effective amount of a composition including Lactobacillus plantarum LP10 with the deposition number CGMCC13008;
wherein reducing muscle fatigue includes increasing muscle mass and muscle endurance; and
wherein the therapeutically effective amount is at least 1010 CFU per day.
US Pat. No. 10,189,711

METHODS AND SYSTEMS FOR RECOVERING PHOSPHORUS FROM WASTEWATER INCLUDING DIGESTATE RECYCLE

Multiform Harvest Inc., ...

1. A method for treating wastewater and producing inorganic phosphorus, comprising: (a) inducing a mixture of microorganisms to grow in the wastewater, thereby taking up phosphorous from the wastewater into the microorganisms cell mass,(b) inducing the mixture of microorganisms containing phosphorus and magnesium to release phosphorus and magnesium to provide a treated mixture that includes phosphorus and magnesium;
(c) subjecting the treated mixture to solids separation to provide a phosphorus- and magnesium-reduced mixture and an ammonia-containing, phosphorus- and magnesium-rich liquid;
(d) conducting the ammonia-containing, phosphorus- and magnesium-rich liquid to an inorganic phosphorus reactor to provide inorganic phosphorus;
(e) anaerobically treating the phosphorus- and magnesium-reduced mixture to provide an ammonia-rich, phosphorus- and magnesium-reduced product; and
(f) conducting at least a portion of the ammonia-rich, phosphorus- and magnesium-reduced product to the treated mixture prior to solids separation in step (c).
US Pat. No. 10,189,968

VARNISH FOR POROUS POLYIMIDE FILM PRODUCTION AND METHOD FOR PRODUCING POROUS POLYIMIDE FILM USING SAME

TOKYO OHKA KOGYO CO., LTD...

1. A varnish comprising a resin, fine particles, and a solvent, whereinthe resin includes polyamide acid and/or polyimide,
a content of the fine particles is not less than 65% by volume with respect to a total of the resin and the fine particles,
the fine particles have a particle diameter distribution index (d25/d75) in a range of not less than 1.6 and not more than 5, and
a viscosity at 25° C. of the varnish is not less than 550 mPa·s.
US Pat. No. 10,188,687

ORIENTAL MEDICINAL COLLAGEN FOOD

Goo Whan Kim, Daejeon (K...

1. An oriental medicinal collagen food for skin beauty enhancement comprising:a dried extract comprising:
Gyepogyo comprising a fermented mixture of pasteurized chicken feet and dandelion extract, wherein claws and scales are removed from the pasteurized chicken feet; and
at least one of angelica gigas and pueraria root.
US Pat. No. 10,188,691

PROTEIN INTERFACES

SyntheX, Inc., San Franc...

1. A non-naturally occurring peptide of fewer than 30 amino acid residues which interacts with RAD51 Associated Protein 1?s (RAD51AP1?s) binding site on human RAD51 recombinase (RAD51), wherein the non-naturally occurring peptide consists of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 66, or SEQ ID NO:67, wherein any of the amino acids are optionally D-amino acids.
US Pat. No. 10,188,692

METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS

Stealth Biotherapeutics C...

1. A method for treating macular degeneration in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide represented by the formula D-Arg-2?6?-Dmt-Lys-Phe-NH2 or Phe-D-Arg-Phe-Lys-NH2, where the subject has drusen.
US Pat. No. 10,189,974

TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A tire composed of a rubber composition which comprises a rubber component comprising a modified butadiene rubber and silica and has a pure water contact angle of from 125° to 140°,wherein the rubber composition comprises the modified butadiene rubber and silica as a masterbatch, and
wherein the masterbatch is made by a kneading step for kneading each of the components, said kneading step comprising:
an X-kneading step for preparing the masterbatch comprising the modified butadiene rubber and silica,
a Y-kneading step of adding the remaining compounding agents and additives other than vulcanizing agents and vulcanization accelerators to the masterbatch and then kneading a resultant mixture, and
a final F-kneading step of adding vulcanizing agents and vulcanization accelerators to the kneaded product obtained in the base kneading step and then kneading a resultant mixture.
US Pat. No. 10,188,693

METHODS FOR TREATMENT OF ATHEROSCLEROSIS

Stealth Biotherapeutics C...

1. A method for delaying onset, ameliorating or eliminating statin side effects in a subject in need thereof, the method comprising administering an effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof, wherein the peptide is chemically linked to the statin, wherein the statin side effect comprises one or more of rhabdomyolysis, kidney failure, diabetes, memory loss, and decreased coenzyme Q10 levels.
US Pat. No. 10,188,694

PEPTIDE FOR SKIN REGENERATION OR WOUND TREATMENT AND USE THEREOF

BIO PEP CO., LTD., Seoul...

1. A peptide selected from the group consisting of the amino acid sequence consisting of SEQ ID NO: 1 or the amino acid sequence consisting of SEQ ID NO: 2, wherein the N- or C-terminal of the peptide is attached to a protective group selected from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or a polyethylene glycol (PEG) group.
US Pat. No. 10,188,697

GLYCOPEPTIDE COMPOSITIONS

XELLIA PHARMACEUTICALS AP...

1. A pharmaceutical composition comprising a glycopeptide antibiotic; an excipient selected from N-acetyl-D-Alanine and N-acetyl-Glycine; and an amino acid.
US Pat. No. 10,189,980

PROCESS FOR PRODUCING THERMOPLASTIC RESIN COMPOSITION

The Yokohama Rubber Co., ...

1. A process for producing a thermoplastic resin composition having a continuous phase comprising (A) an ethylene-vinyl alcohol copolymer and (B) a polyamide resin (B) and a dispersed phase comprising (C) an acid-modified polyolefin elastomer, wherein the process comprising:(I) kneading the ethylene-vinyl alcohol copolymer (A) and the acid-modified polyolefin elastomer (C) to form a kneaded material in which the acid-modified polyolefin elastomer (C) is dispersed in the ethylene-vinyl alcohol copolymer (A), subsequently,
(II) adding the polyamide resin (B) to the kneaded material obtained in step (I) and further kneading them, and subsequently,
(III) adding an end-capping agent (D) for the polyamide resin (B) in an amount of 0.1 to 5 parts by weight based on 100 parts by weight of the polyamide resin (B) to a kneaded material obtained in step (II) and melt-kneading them at or above the melting point of the polyamide resin (B).
US Pat. No. 10,189,984

THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE

LG CHEM, LTD., Seoul (KR...

1. A thermoplastic resin composition, comprising:100 parts by weight of a base resin that comprises greater than 0% by weight to 35% by weight of a diene-based graft copolymer, greater than 0% by weight to 30% by weight of an acrylic graft copolymer, and 35 to 85% by weight of a copolymer of a vinyl cyanide compound and an aromatic vinyl compound; and
greater than 1 part by weight of a polyester-based elastomer having a melt index of 0.1 to 10 g/10 min (230° C., 2.16 kg).
US Pat. No. 10,188,703

METHOD FOR TREATING DIABETES MELLITUS BY A COMPOSITION COMPRISING INSULIN AND A GLP-1/GLUCAGON DUAL AGONIST

HANMI PHARM. CO., LTD., ...

1. A method for treating diabetes mellitus, comprising administering a pharmaceutical composition to a subject at high risk of or having the diabetes mellitus, wherein the composition comprises a long-acting insulin conjugate and a long-acting glucagon-like peptide (GLP-1)/glucagon dual agonist conjugate,wherein the long-acting insulin conjugate is a conjugate in which insulin is linked to an immunoglobulin Fc region via a non-peptidyl polymer; and
wherein the long-acting GLP-1/glucagon dual agonist conjugate is a conjugate in which a GLP-1/glucagon dual agonist is linked to an immunoglobulin Fc region via a non-peptidyl polymer.
US Pat. No. 10,189,992

RESIN COMPOSITION AND SEAL MEMBER USING SAME

MITSUBISHI CABLE INDUSTRI...

1. A resin composition for a resin sealing member, comprising(b) 1 part by weight-7 parts by weight of a powder of a compound having a layer crystal structure, and
(c) 8 parts by weight-27 parts by weight of a native polytetrafluoroethylene powder, per (a) 100 parts by weight of polyether sulfone.
US Pat. No. 10,188,712

TUMOR ANTIGENS FOR DETERMINING CANCER THERAPY

BIONTECH AG, (DE)

1. A method for treating triple negative breast cancer in a patient comprisinga) detecting the expression pattern of a set of tumor antigens in a sample from the patient, wherein the set of tumor antigens comprises CXorf61, CAGE1, and PRAME;
b) diagnosing the patient as needing a cancer therapy regimen when CXorf61, CAGE1, and PRAME are expressed; and
c) treating the patient with an immunotherapeutic that targets the set of tumor antigens expressed in the patient.
US Pat. No. 10,189,995

ASPHALT COMPOSITION

Asahi Kasei Kabushiki Kai...

1. An asphalt composition, comprising0.5 parts by mass or more and 20 parts by mass or less of a block copolymer, and
100 parts by mass of an asphalt;
wherein the block copolymer comprises a polymer block (A) mainly comprising a vinyl aromatic monomer unit, and a copolymer block (B) comprising a conjugated diene monomer unit and a vinyl aromatic monomer unit; the content of the vinyl aromatic monomer unit in the block copolymer being 20% by mass or more and 60% by mass or less;
wherein a content of the polymer block (A) in the block copolymer is 10% by mass or more and 40% by mass or less;
wherein a hydrogenation rate of a double bond in the conjugated diene monomer unit of the block copolymer is 40% or more and 100% or less;
wherein the asphalt has a colloidal index ((a saturate fraction content+an asphaltene fraction content)/(a resin fraction content+an aromatic fraction content)) of 0.30 or more and 0.54 or less, and a saturate fraction content of 11% by mass or less,
wherein the conjugated diene monomer unit of the block copolymer comprises a conjugated diene monomer unit (a) derived from a 1,2-bond and/or a 3,4-bond and a conjugated diene monomer unit (b) derived from a 1,4-bond, and
wherein a total content of the conjugated diene monomer units is 100% by mass,
wherein a content of an alkenyl monomer unit (a1) in the conjugated diene monomer unit (a) hydrogenated is 10% by mass or more and 50% by mass or less,
wherein a content of an alkenyl monomer unit (b1) in the conjugated diene monomer unit (b) hydrogenated is 0% by mass or more and 80% by mass or less, and
wherein a sum of contents of a non-hydrogenated conjugated diene monomer unit (a2) after hydrogenation and a non-hydrogenated conjugated diene monomer unit (b2) after hydrogenation is 0% by mass or more and 90% by mass or less.
US Pat. No. 10,188,716

PROTECTIVE ANTIGEN COMPLEXES WITH INCREASED STABILITY AND USES THEREOF

Wichita State University,...

1. A method for inducing an immunogenic response in a subject against B. anthracis, said method comprising administering to the subject a therapeutically-effective amount of an immunogenic composition against Bacillus anthracis, said composition comprising a stabilized protective antigen complex, said complex comprising Bacillus anthracis protective antigen protein and capillary morphogenesis protein-2, wherein said capillary morphogenesis protein-2 is bound to said protective antigen protein along a binding interface.
US Pat. No. 10,188,720

RECOMBINANT MAREK'S DISEASE VIRUSES AND USES THEREOF

CEVA SANTE ANIMALE, Libo...

1. A recombinant Marek's disease virus of serotype 1 (MDV1) which comprises (1) a promoter of 274 nucleotides in length consisting of SEQ ID NO: 5 or consisting of a sequence having at least 90% sequence identity to SEQ ID NO: 5 and exhibiting transcriptional promoter activity and (2) under the control of said promoter, a recombinant nucleotide sequence encoding a polypeptide.
US Pat. No. 10,190,003

DEGRADATION-RESISTANT SCALE INHIBITORS

Cytec Industries Inc., , ...

1. A method of reducing aluminosilicate containing scale in a Bayer process, comprising:identifying a Bayer process equipment surface that is subject to scale formation during the Bayer process;
contacting the identified Bayer process equipment surface with an amount of a scale inhibiting composition effective to form a treated surface that is more resistant to scale formation upon subsequent contact with a Bayer process stream than an otherwise comparable untreated surface; and
contacting the treated surface with the Bayer process stream;
wherein the scale inhibiting composition comprises a liquor comprising an aqueous solution of one or more water-soluble salts having at least about 0.004% by weight of total dissolved salts and a silicon-containing compound,
wherein the silicon-containing compound is resistant to degradation in alumina recovery process streams at process temperatures from about 100° C. to about 265° C.,
wherein the silicon-containing compound is a reaction product of at least a polyamine, a first nitrogen-reactive compound and a second nitrogen-reactive compound,
wherein:
the first nitrogen-reactive compound comprises a —Si(OR1b)3 group and a nitrogen-reactive group, where R1b is H, optionally substituted C1-C20 alkyl, optionally substituted C6-C12 aryl, optionally substituted C7-C20 aralkyl, optionally substituted C2-C20 alkenyl, Group I metal ion, Group II metal ion, or NR2b4, each R2b being independently selected from H, optionally substituted C1-C20 alkyl, optionally substituted C6-C12 aryl, optionally substituted C7-C20 aralkyl, or optionally substituted C2-C20 alkenyl;
the second nitrogen-reactive compound comprises a nitrogen-reactive group and does not contain a —Si(OR1b)3 group, and
wherein the silicon-containing compound is free of ?-hydroxy ether groups.
US Pat. No. 10,188,722

LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT

Aviex Technologies LLC, ...

1. A live genetically engineered Salmonella bacterium, having:a first loss-of-function mutation of the MsbB gene; and
a second loss-of-function mutation of the zwf gene,
being further genetically engineered to express at least one heterologous protein comprising an antigen adapted to act as a vaccine in a mammalian host,
wherein the live genetically engineered Salmonella bacterium having the first loss of gene function mutation and the second loss of gene function mutation has resistance to CO2, osmolarity and acidic pH, and reduced TNF-? induction capacity in the mammalian host after administration of a pharmaceutical dosage form containing the live genetically engineered Salmonella bacterium, relative to a wild type Salmonella bacterium of the respective live genetically engineered Salmonella bacterium having the first loss of gene function mutation of MsbB and not the second loss of gene function of zwf.
US Pat. No. 10,190,005

PAINTS, LACQUERS OR OTHER COATING MATERIALS WITH ANTI-PINHOLE ADDITIVE AND THE MANUFACTURE AND USE THEREOF

Hemmelrath Technologies G...

1. A process for applying a coating, which is in the form of a paint, a lacquer, or another coating material in a liquid solution, to a workpiece in order to obtain a pinhole-free surface, the method comprising:providing an anti-pinhole additive comprising hydrophilic pyrogenic silica;
determining whether the workpiece has been contaminated by silane or silanol compounds;
adding the anti-pinhole additive to the coating when the workpiece is determined to be contaminated by silane or silanol compounds; and
applying the coating to the surface of the workpiece.
US Pat. No. 10,189,749

HUMIC ACID LIGNITE COAL BASED LIQUID FERTILIZER

Innovative Crop Solutions...

1. A fertilizer composition prepared by a process comprising:(a) preparing a mixture consisting essentially of liquid nitrogen and lignite;
(b) mixing the liquid nitrogen and lignite;
(c) adding phosphoric acid to the mixture;
(d) mixing the phosphoric acid with the mixture;
(e) adding water to the mixture and phosphoric acid to form a solution;
(f) mixing the water with the solution;
(g) adding potash to the solution;
(h) mixing the potash into the solution;
(i) filtering the solution, wherein filtering is performed by gravity filtration; and
(j) placing the solution into a container.
US Pat. No. 10,190,011

INK JET RECORDING METHOD, INK JET INK COMPOSITION, AND INK SET

Seiko Epson Corporation, ...

1. An ink jet recording method comprising:forming a first image layer by ejecting a first ink composition that contains resin particles, an organic solvent, and water on a recording medium by an ink jet method;
first drying in which 80% by mass or more of water contained in the first ink composition of the first image layer is evaporated; and
forming a second image layer by ejecting a second ink composition that contains water, and an organic solvent by which the resin particles contained in the first ink composition dissolve or swell on the first image layer subjected to the first drying by the ink jet method,
wherein the content of an organic solvent having a normal boiling point of higher than 250° C. in the first ink composition and the second ink composition is 2% by mass or less, respectively.
US Pat. No. 10,188,730

ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

1. An antibody or antigen-binding fragment thereof that specifically binds human LAG3 comprising:a light chain variable domain comprising:
CDR-L1 that comprises the amino acid sequence: KASQSLDYEGDSDMN (SEQ ID NO: 38);
CDR-L2 that comprises the amino acid sequence: GASNLES (SEQ ID NO: 39); and
CDR-L3 that comprises the amino acid sequence: QQSTEDPRT (SEQ ID NO: 40); and
a heavy chain variable domain comprising:
CDR-H1 that comprises the amino acid sequence: DYNVD (SEQ ID NO: 33);
CDR-H2 that comprises the amino acid sequence: DINPNDGGTIYAQKFQE (SEQ ID NO: 457); and
CDR-H3 that comprises the amino acid sequence: NYRWFGAMDH (SEQ ID NO: 35).
US Pat. No. 10,188,987

MULTIFUNCTIONAL FILTERS FOR DIESEL EMISSION CONTROL

BASF Corporation, Florha...

1. A catalyzed particulate filter comprising:a plurality of porous walls extending longitudinally to form a plurality of parallel passages extending from an inlet end to an outlet end, wherein a quantity of the passages are inlet passages that are open at the inlet end and closed at the outlet end, and a quantity of passages are outlet passages that are closed at the inlet end and open at the outlet end;
at least three coatings creating at least two zones axially along the plurality of porous walls, wherein a first coating is a first SCR catalyst coating, a second coating is a second SCR catalyst coating, and a third coating is a platinum group metal coating.
US Pat. No. 10,188,732

METHODS AND COMPOSITIONS FOR INACTIVATING ENVELOPED VIRUSES

Biogen MA Inc., Cambridg...

1. A method of inactivating an enveloped virus in a recombinant protein preparation, the method comprising contacting a recombinant protein preparation that comprises a recombinant protein with N,N-dimethyldodecyclamine N-oxide (LDAO) in an amount sufficient to inactivate the enveloped virus, wherein the amount is at a concentration above critical micelle concentration of the LDAO and does not inhibit biological activity of the recombinant protein.
US Pat. No. 10,190,014

SURFACE-TREATING AGENT FOR VULCANIZED RUBBER

NOK Corporation, Tokyo (...

1. A surface-treating agent for vulcanized rubber wherein the surface-treating agent comprises, based on 100 parts by weight, as solid matters, of isocyanate group-containing 1,2-polybutadiene, an organic solvent solution containing 10 to 160 parts by weight of fluororesin particles and 2.5 to 20 parts by weight of a perfluoroalkyl group-containing oligomer-based, fluorine-containing surfactant as a dispersant, and further comprises, based on 100 parts by weight, as solid matters, of the isocyanate group-containing 1,2-polybutadiene, 100 parts by weight or less, as solid matters, of a composition solution of an OH group-containing fluororesin composition having the following formulation:[I] a copolymer of
(A) a perfluoroalkylalkyl (meth)acrylate and
(B) a hydroxyl group-containing (meth)acrylate,
[II] a polymer of an acrylic acid alkyl ester,
[III] a polymer of a fluorinated olefin, and
[IV] a curing agent; and/or
60 parts by weight or less of silicone oil having a viscosity of 8,000 cs or more.
US Pat. No. 10,190,019

MULTISTAGE POLYMERS AND COMPOSITIONS THEREOF

BASF SE, Ludwigshafen (D...

1. A multilayer particle comprising(i) a first layer comprising a first copolymer derived from a soft ethylenically-unsaturated monomer, a phosphorus-containing monomer, and an acetoacetoxy monomer; and
(ii) a second layer surrounding at least a portion of the first layer comprising a second polymer derived from at least 90% by weight of one or more hard ethylenically-unsaturated monomers selected from the group consisting of methyl methacrylate, styrene, and combinations thereof, based on the total weight of monomers used to form the second polymer;wherein the particle exhibits a single Tg, measured using DSC, ranging from ?10° C. to 25° C.
US Pat. No. 10,188,739

COMPOSITIONS AND METHODS FOR ADMINISTERING INSULIN OR INSULIN-LIKE PROTEIN TO THE BRAIN

XENETIC BIOSCIENCES, INC....

1. A method of administering a therapeutically effective amount of an insulin to the brain of an individual, the method comprising intranasal administration of a pharmaceutical composition comprising a population of the insulin and/or an insulin-like protein attached to a polysialic acid where administration results in a therapeutically effective amount in the brain but not the serum of the individual.
US Pat. No. 10,191,045

SOL COMPOSITION FOR SOL-GEL BIOCHIP TO IMMOBILIZE PROBE ON SUBSTRATE WITHOUT SURFACE TREATMENT AND METHOD AND SCREENING THEREOF

So Youn Kim, Seoul (KR)

1. A method for screening a sol composition for sol-gel biochips, which is used to immobilize a probe on a surface-untreated substrate, the method comprising the steps of:(a) obtaining a first library of sol compositions wherein at least one silicate monomer selected from the group consisting of tetramethylorthosilicate (TMOS), methyltrimethoxysilane (MTMOS), tetraethylorthosilicate (TEOS), ethyltrimethoxysilane (ETrEOS), trimethoxysilane (TMS), methyltrimethoxysilicate (MTMS) and 3-aminopropyltrimethoxysilicate (3-ATMS), and at least one additive selected from the group consisting of polyglyceryl silicate (PGS), diglyceryl silane (DGS), 3-glycidoxypropyl trimethoxysilane (GPTMOS), (N-triethoxysilylpropyl)-0-polyethylene oxide urethane (PEOU), glycerol and polyethylene glycol (PEG) having a molecular weight of 100-10,000, are mixed with each other in buffer at various ratios;
(b) spotting the first library of sol compositions on a surface-untreated target substrate;
(c) measuring the adhesion, appearance, transmittance and gelling time of the spots formed in the step (b), and selecting, based on the measurement results, compositions, which do not show the detachment of spots even when they are scratched with a tip after washing, have a spot diameter of 100-800 ?m while maintaining a circular shape, show a self-fluorescence lower than background fluorescence, and have a gelling time of 4-48 hours in a tube and a gelling time of 1-4 hours on the spots of the substrate, thereby obtaining a second library of sol com positions;
(d) adding a probe to the second library of sol compositions and spotting the probe-containing second library on a surface-untreated substrate; and
(e) measuring the immobilization rate of the spots for the probe, and the specificity between the probe and a target substance, and selecting, based on the measurement results, a sol composition wherein the immobilization rate of the probe is at least 70% and the ratio of specific signals/non-specific signals of the probe and the target substance is at least 3.
US Pat. No. 10,190,022

ANTIFOULING COMPOSITION, ANTIFOULING SHEET, AND METHOD FOR MANUFACTURING ANTIFOULING SHEET

LINTEC CORPORATION, Itab...

1. An antifouling composition comprising a polysilazane-based compound (A) and a both terminal carboxy-modified silicone (B),wherein a content of the silicone (B) is from 0.01 to 10 parts by mass based on 100 parts by mass of a total amount of the compound (A), and the antifouling composition is suitable for use as a sheet-like antifouling layer-forming material.
US Pat. No. 10,188,999

PROCESS FOR ENCAPSULATING A LIQUID

Fondazione Istituto Itali...

1. Process for the production of globular microstructures comprising a liquid core and a solid shell that envelops the core, in which said solid shell is impervious to water and is formed from hydrophobic polymeric micro- or nanofibres, the method comprising:dropping droplets of liquid on a mat of polymeric micro- or nanofibres obtained by electrospinning, and
rolling said droplets on said mat of fibres, so as to extract micro- or nanofibres that are not intertwined with one another from said mat and form said shell on the surface of the liquid core.
US Pat. No. 10,189,770

PRODUCTION METHOD OF HIGHLY UNSATURATED FATTY ACID ETHYL ESTER

Bizen Chemical Co., Ltd.,...

1. A method of purifying highly unsaturated fatty acid derivatives from a mixture comprising highly unsaturated fatty acid derivatives, comprising a step selected from the group consisting of the following (1) to (4):(1) (a) providing the mixture having a peroxide value (POV) of 1 or smaller, wherein the peroxide value of the mixture is adjusted by a POV reducing agent, and
(b) contacting the mixture with an aqueous solution of silver salt;
(2) (a) providing the mixture having a peroxide value of 1 or smaller, wherein the peroxide value of the mixture is adjusted by a POV reducing agent, and
(b) mixing the mixture with an aqueous solution of silver salt;
(3) (a) decreasing a peroxide value of the mixture to 1 or smaller by contacting the mixture with a POV reducing agent, and
(b) contacting the mixture with an aqueous solution of silver salt; and
(4) (a) decreasing a peroxide value of the mixture to 1 or smaller by contacting the mixture with a POV reducing agent, and
(b) mixing the mixture with an aqueous solution of silver salt,
wherein the derivatives comprise at least one of a methyl ester, ethyl ester, amide, methyl amide, triglyceride, diglyceride or monoglyceride derivative.
US Pat. No. 10,188,749

COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS

FRED HUTCHINSON CANCER RE...

1. A method of selectively modifying a selected cell population of hematopoietic origin comprising:(a) forming selected cell-targeted synthetic nanocarriers by
(i) adding polyglutamic acid (PGA) conjugated to selected cell targeting ligands that bind the selected cell population of hematopoietic origin to a solution comprising nucleic acid encapsulated within a positively-charged carrier comprising poly(?-amino ester); and
(ii) incubating the solution wherein selected cell-targeted synthetic nanocarriers form within 5 minutes of the adding and comprise
(A) nucleic acid encapsulated within the positively-charged carrier comprising poly(?-amino ester);
(B) a neutrally or negatively-charged coating comprising about a 15 kDa PGA on the outer surface of the positively-charged carrier; and
(C) the selected cell targeting ligands extending from the outer surface of the neutrally or negatively-charged coating and conjugated to PGA within the neutrally or negatively-charged coating; and
(b) administering the formed selected cell-targeted synthetic nanocarriers to a heterogenous mixture of ex vivo cells comprising the selected cell population of hematopoietic origin within a serum-free media thereby selectively modifying the selected cell population of hematopoietic origin.
US Pat. No. 10,190,031

THERMALLY CONDUCTIVE INTERFACE COMPOSITION AND USE THEREOF

Jiali Wu, Yorktown Heigh...

1. A thermally conductive interface composition, comprising:(A) A linear alkenyl organopolysiloxane containing a silicon-bonded alkenyl-terminated group or groups in an average amount of 0.0001 to 5 mol % based on the amount of all silicon-bonded organic groups contained per molecule;
(B) A branched alkenyl organopolysiloxane containing at least two silicon-bonded alkenyl groups in an average amount of about 0.01 to 1 mol % based on the amount of all silicon-bonded organic groups contained per molecule, with component (A) to (B) ratio of 20:1 to 1:20;
(C) Thermally conductive fillers in a ternary particle size mixture with large particle in the average size range of 50-500 um, small particle in the average size range of 0.5-200 um, and nanoparticle in the average size range of 10-2000 nm;
(D) An organohydrogenpolysiloxane containing at least two Si—H terminated groups presented at terminal or intermediate positions of the molecule, with 0.5-0.8 moles of SiH groups per mole of alkenyl groups in component (A) and (B);
(E) An addition reaction catalyst;
(F) A hydroxy group-containing siloxane in an amount corresponding to 0.0001-5% of the weight of component (A) and (B) combined;
(G) A mixture of at least two alkoxy group-containing siloxanes adhering to formula (5) differing in the value of “n” added in an amount corresponding to 0.001-5% of the weight of component (C)
(R8O)pSiR93-p[OSiR82]n(OR8)qR93-q  (5)
wherein R8 and R9 represent a substituted or unsubstituted monovalent hydrocarbon group, p is an integer of 1, 2, 03, q is an integer of 1, 2, or 3, and n is an integer of 1 to 150.
US Pat. No. 10,189,009

PARTICULATE WATER ABSORBING AGENT AND METHOD FOR MANUFACTURING SAME

NIPPON SHOKUBAI CO., LTD....

1. A method for producing a particulate water absorbing agent, the particulate water absorbing agent being arranged such that particles having passed through a 150-?m mesh as defined through a standard-sieve classification are contained in an amount of 3 mass % or less, the method comprising the steps of:(1) polymerizing a monomer aqueous solution including acrylic acid (salt) as a main component, the monomer aqueous solution having a monomer concentration of 30 mass % or more, the polymerization involving use of an internal crosslinking agent in an amount of 0.04 mol % or more and 0.07 mol % or less relative to the monomer and producing a hydrogel;
(2) drying the hydrogel, produced through the step (1), to produce a dried product having a swelling rate (CRC) of 35 g/g to 55 g/g;
(3) pulverizing the dried product into particles and optionally classifying the particles to produce a water absorbent resin powder including, at 80 mass % or more relative to the entire water absorbent resin powder, a particle having a size of 600 ?m to 150 ?m as defined through a standard-sieve classification;
(4) adding a surface-crosslinking agent, which includes a compound containing a hydroxyl group and/or a derivative group thereof, to the water absorbent resin powder, produced through the step (3), to decrease the swelling rate (CRC) by 3 g/g to 15 g/g to a swelling rate (CRC) of 32 g/g to 50 g/g to produce a surface-crosslinked water absorbent resin powder, and
(5) adding a liquid permeability improving agent to the water absorbent resin powder simultaneously with and/or after the step (4).
US Pat. No. 10,189,012

PREPARATION OF CATALYST

SHELL OIL COMPANY, Houst...

1. A process for hydrocracking a hydrocarbonaceous feedstock, which process comprises: contacting a gaseous feedstock at a reaction temperature in the range of 250 to 500° C. and a total pressure at the reactor inlet in the range of from 3×106 to 3×107 Pa in the presence of hydrogen with a hydroconversion catalyst in which the gaseous feedstock contains less than 150 parts per million by weight of ammonia;wherein said hydroconversion catalyst is made by the method comprising;
(a) preparing an aqueous mixture containing aluminum sulfate and having a pH in the range of from 1.0 to 6.5;
(b) adding alkali metal aluminate to the mixture obtained in step (a) to increase the pH of the mixture to within the range of from 7.1 to 12;
(c) adding aluminum sulfate to the mixture obtained in step (b) to lower the pH of the mixture to within the range of from 1.5 to 6.5;
(d) adding alkali metal silicate to the mixture obtained in step (c) to increase the pH of the mixture to within the range of from 6.5 to 11;
(e) adding aluminium sulfate to the mixture obtained in step (d) to lower the pH of the mixture to within the range of from 1.5 to 7.0; and
(f) adding alkali metal aluminate to the mixture obtained in step (e) to increase the pH of the mixture to within the range of from 7.5 to 12,
wherein the final steps of the preparation process are;
(v) adding aluminum sulfate to the mixture obtained in a process comprising steps (a)-(d) to lower the pH of the mixture to within the range of from 2 to 8;
(w) adding alkali metal silicate to the mixture obtained in step (v) to increase the pH of the mixture,
(x) adding to the mixture obtained in step (w) (i) alkali metal aluminate to change the pH of the mixture to of from 7.8 to 12 and (ii) aluminum sulfate to change the pH of the mixture to within the range of from 1.5 to 7.7, wherein step (i) can precede or succeed step (ii),
(y) treating the mixture obtained in step (x) with an alkali metal hydroxide solution having a pH of from 7.5 to 12,
(z) recovering a precipitate solid from the mixture obtained in step (y) to provide a recovered precipitate;
(zz) washing with water the recovered precipitate and drying the recovered and washed precipitate by flash drying, belt drying or spray drying to obtain a dried silica-alumina composition containing of from 30 to 70% wt silica and of from 70 to 30% wt of alumina, and having a surface area of from 320 m2/g to 450 m2/g, and
subsequently shaping the dried silica-alumina composition to provide a shaped silica-alumina composition and compositing the shaped silica-alumina composition with one or more metals or metal compounds which metals have been selected from the group consisting of Group VIB and Group VIII metals to obtain a hydrocarbon conversion catalyst.
US Pat. No. 10,189,013

MONOLITHIC CATALYST COMPRISING MOLECULAR SIEVE MEMBRANE AND METHOD FOR PREPARING THE MONOLITHIC CATALYST

WUHAN KAIDI ENGINEERING T...

1. A method for preparing a monolithic catalyst comprising:cobalt;
a matrix, the matrix comprising at least one metal selected from the group consisting of silver, gold, copper, platinum, titanium, molybdenum, iron, and tin;
an additive, the additive being lanthanum, zirconium, cerium, rhodium, platinum, rhenium, ruthenium, titanium, magnesium, calcium, strontium, or a mixture thereof; and
a molecular sieve membrane, the molecular sieve membrane being mesoporous silica SBA-16 which is disposed on a surface of the metal matrix and is a carrier of the cobalt and the additive;
wherein
a thickness of the carrier of the molecular sieve membrane is between 26 and 67 ?m, the method comprising:
1) washing a plurality of metal matrixes having a honeycomb-shape and uniform sizes using deionized water; and drying the metal matrixes in an oven at 100° C.;
2) dissolving molecular sieve powders of the mesoporous silica SBA-16 in absolute ethanol to yield a mixture; oscillating the mixture for 20 to 30 min using an ultrasonic oscillation method to form a uniformly distributed soak solution of the molecular sieve powders; soaking the metal matrixes pretreated in 1) in the soak solution for 1 to 10 s; taking the metal matrixes out, and when the soak solution on the metal matrixes stops flowing and dripping down, soaking the metal matrixes in the soak solution again; repeating the impregnation of the metal matrixes, and then drying the metal matrixes in air;
3) placing the metal matrixes obtained in 2) in a molecular sieve solution of mesoporous silica SBA-16 and crystallizing the mesoporous silica SBA-16 for 5 to 120 hrs at a temperature of between 70 and 150° C. in a reaction still; allowing the mesoporous silica SBA-16 to grow in-situ on a surface of the metal matrixes to yield metal matrixes comprising a molecular sieve membrane; taking out the metal matrixes comprising the molecular sieve membrane, washing the metal matrixes comprising the molecular sieve membrane using deionized water, and drying; and roasting the metal matrixes comprising the molecular sieve membrane for 4 to 8 hrs at a temperature of between 400 and 600° C.; and
4) soaking the metal matrixes comprising the molecular sieve membrane obtained in 3) in a solution of a cobalt salt and the additive for 1 to 20 min; drying the metal matrixes comprising the molecular sieve membrane and aging at room temperature for 3 to 36 hrs; roasting the metal matrixes comprising the molecular sieve membrane for 6 to 12 hrs at a programmed temperature of between 300 and 550° C., and then gradually cooling the metal matrixes comprising the molecular sieve membrane to room temperature.
US Pat. No. 10,189,016

NANO-TO-NANO FE/PPM PD CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER

THE REGENTS OF THE UNIVER...

1. An aqueous micellar composition in a reaction solvent for enabling cross-coupling reactions containing organometallic nanoparticles (NPs) as catalyst, comprising:a) an element selected from the group consisting of Fe, C, H, O, Mg, and a halide, or the entire combination thereof; and
b) palladium (Pd), or at least one other metal selected from the group consisting of Pt, Au, Ni, Co, Cu and Mn, or a mixture thereof; wherein the catalyst (NPs) is prepared from a reduction of an iron salt or an iron complex in a solvent and in the presence of a ligand using a reducing agent.
US Pat. No. 10,191,068

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43

ARIZONA BOARD OF REGENTS ...

1. An antibody fragment comprising an amino acid sequence encoded by a nucleic acid, wherein the nucleic acid has at least 96% identity to SEQ ID NO:1.
US Pat. No. 10,191,070

METHODS AND SYSTEMS FOR MEASURING SEROTONIN IN A SAMPLE

Laboratory Corporation of...

1. A method for determining amount of released serotonin in a sample, the method comprising:providing a sample comprising a biological sample, donor platelets, and heparin;
incubating the sample for a period of time to release serotonin from the donor platelets;
chromatographically separating serotonin from other components in the incubated sample using liquid chromatography; and
analyzing the chromatographically separated serotonin by mass spectrometry to determine the amount of released serotonin in the sample relative to a total amount of serotonin available in the donor platelets.
US Pat. No. 10,193,144

HIGH CAPACITY LITHIUM ION BATTERIES HAVING OXIDES, PEROXIDES, OR SUPEROXIDES AS CATHODE ACTIVE MATERIAL

UCHICAGO ARGONNE, LLC, C...

1. A cathode comprising an electroactive material comprising LO2 or L2O2, wherein each L is independently selected from Li, Na, K, Be, Mg, Ca, and Al; the electroactive material is metal-coated, metal oxide-coated, or doped; the electroactive material has less than or equal to 10 wt. % of transition metal catalyst; and the electroactive material is non-cycled active material, wherein the electroactive material is doped with Li, Na, K, Be, Mg, Ca, Al, Cu, Mn, Nd, Ag, Ti, Ni, Cd, Ir, Ta, Y, Zr, Nb, Rh, or Cr.
US Pat. No. 10,188,793

INSULIN ON BOARD CALCULATION, SCHEDULE AND DELIVERY

Bigfoot Biomedical, Inc.,...

1. An insulin delivery system comprising:an insulin delivery device configured to deliver insulin to a user of the system; and
a computer-based control unit associated with the insulin delivery device, the computer-based control unit having a computer-based processor, wherein the computer-based processor is configured to:
calculate a relative insulin on board value for a specific time by calculating a first value that represents a reference insulin on board value at the specific time, calculating a second value that represents an automated insulin on board value at the specific time, and subtracting one of the first and second values from the other;
determine a future insulin delivery schedule over a period of time based in part on the calculated relative insulin on board value; and
configure the insulin delivery device to deliver insulin according to the determined future insulin delivery schedule, and
wherein the automated insulin on board value represents at least one insulin delivery automatically specified by the computer-based control unit.
US Pat. No. 10,190,093

ARTIFICIAL OOCYTE ACTIVATION

The Curators of the Unive...

1. A method of activating an unfertilized porcine oocyte comprising decreasing intracellular Zn2+ concentration of the oocyte by contacting the oocyte with a Zn2+ binding moiety comprising approximately 200 mM TPEN (N,N,N?,N?-tetrakis(2-pyridylmethyl)ethane-1,2-diamine), and increasing intracellular Ca2+ concentration of the oocyte prior to decreasing the intracellular Zn2+ concentration of the oocyte, wherein the intracellular Ca2+ concentration of the oocyte is not increased in an amount sufficient to induce oocyte activation, and wherein said contacting results in activating the oocyte.
US Pat. No. 10,189,837

CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT

Medivation Technologies L...

4. A pharmaceutical composition comprising the crystalline tosylate salt of claim 1 and a pharmaceutically acceptable excipient.
US Pat. No. 10,190,102

LACCASE VARIANTS WITH IMPROVED PROPERTIES

METGEN OY, Kaarina (FI)

1. A polypeptide with laccase activity comprising an amino acid sequence that is at least 94% identical to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 31-61, wherein the polypeptide comprises a non-polar amino acid residue selected from the group consisting of methionine, leucine, isoleucine, valine, proline, glycine, and phenylalanine at an amino acid position corresponding to position 113 in SEQ ID NO: 1.
US Pat. No. 10,188,055

WATERMELON LINE ACE PLUS

SAKATA SEED AMERICA, INC....

1. A seed of watermelon line Ace Plus, wherein a representative sample of seed of said line was deposited under ATCC Accession No. PTA-125206.
US Pat. No. 10,190,109

METHODS FOR OBTAINING POSITIVE TRANSFORMANTS OF A FILAMENTOUS FUNGAL HOST CELL

Novoyzmes, Inc., Davis, ...

1. A filamentous fungal host cell, comprising: a tandem construct comprising (i) one or more selectable markers, (ii) a first polynucleotide encoding a first polypeptide having biological activity operably linked to a first promoter and a first terminator, and (iii) a second polynucleotide encoding a second polypeptide having biological activity operably linked to a second promoter and a second terminator, wherein the tandem construct integrated by ectopic integration into the chromosome of the filamentous fungal host cell, wherein the tandem construct further comprises a first homologous repeat flanking 5? of the one or more selectable markers and a second homologous repeat flanking 3? of the one or more selectable markers, wherein the first homologous repeat and the second homologous repeat undergo homologous recombination to excise the one or more selectable markers, and wherein upon the excision of the one or more selectable markers, the one or more selectable markers can be reused for introducing another tandem construct into the filamentous fungal host cell.
US Pat. No. 10,193,187

IONIC LIQUIDS FOR SOLVATING LITHIUM POLYSULFIDES

NOHMS Technologies, Inc.,...

1. A method of controlling the solvation of polysulfide anions in a mixture by incorporating a plurality of a functionalized single ionic liquid molecule described by the formula C+A?, whereina. A? is an anion selected from the group consisting of halides, nitrates, phosphates, imides, borates, phosphazines, acetates, and sulfonates; and
b. C+ is an organic cation selected from the group consisting of ammoniums, sulfoniums, phosphoniums, and any 5 or 6 membered heterocyclic ring having 1 to 3 heteroatoms as ring members selected from nitrogen, oxygen, and sulfur,wherein one or more of the atoms in the heterocyclic ring of the cation are substituted with one or more moieties selected from the group consisting of halides, oxygen, nitrogen, sulfur, phosphorus, alkanes, esters, ethers, ketones, carbonyls, alkoxyalkanes, alkenes, alkynes, aryls, nitriles, silanes, sulfones, thiols, phenols, hydroxyls, amines, imides, aldehydes, carboxylic acids, carbonates, and acid anhydrides; andwherein any of the carbon or hydrogen atoms in the above moieties are further substituted with halides, oxygen, nitrogen, sulfur, phosphorus, alkanes, esters, ethers, ketones, carbonyls, alkoxyalkanes, alkenes, alkynes, aryls, nitriles, silanes, sulfones, thiols, phenols, hydroxyls, amines, imides, aldehydes, carboxylic acids, carbonates, and acid anhydrides.
US Pat. No. 10,189,086

METHOD AND APPARATUS FOR MANUFACTURING POROUS THREE-DIMENSIONAL ARTICLES

ARCAM AB, Moelndal (SE)

1. A method for manufacturing a porous three-dimensional article comprising the steps of:creating a model of a non-porous three-dimensional article comprising a predetermined number of layers with a predetermined thickness;
creating a model of a porous structure, said creating step comprising the steps of:
defining a completely randomized three-dimensional space comprising a randomized arrangement of nodes, said randomized arrangement of nodes defined by the steps of:
a. identifying a predetermined number of said nodes initially arranged randomly in the three-dimensional space of predetermined size;
b. determining a maximum number of neighbor nodes to a specific node;
c. skipping a number x of closest neighbors to said specific node where x is a random integer number being ?0;
d. connecting each of said maximum neighbor nodes, with the exception of the skipped nodes, to said specific node with a strut; and
e. repeating steps a-d for each node in the three-dimensional space,
wherein said nodes are connected together in the randomized arrangement using struts, wherein said randomized arrangement is randomized in every direction of the completely randomized three-dimensional space, and wherein said randomized arrangement lacks periodicity, such that due to the lacking periodicity, a mechanical strength of a porous structure created therefrom is equal in all directions;
slicing said completely randomized three-dimensional space into a predetermined number of layers with a predetermined thickness;
applying one layer of said model of the non-porous three-dimensional article on one layer of said randomized three-dimensional space resulting in a model of a porous layer of said porous three-dimensional article; and
repeating said applying step for all layers of said model of the non-porous three-dimensional article; and
manufacturing the porous three-dimensional article by exposing fusible material to an energy source, so that a layer of fused material is corresponding to the model of the porous layer of said porous three-dimensional article,
wherein said porous three-dimensional article lacks periodicity.
US Pat. No. 10,188,065

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH316064

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH316064, produced by crossing a first plant of variety CV833038 with a second plant of variety CV950930, wherein representative seeds of said varieties CV833038 and CV950930 are deposited under ATCC Accession Nos. PTA-124484 and PTA-121094, respectively.
US Pat. No. 10,188,070

SOYBEAN CULTIVAR CL1460155

Syngenta Participations A...

1. A plant, a plant part, or a seed of soybean variety CL1460155, wherein a representative sample of seed of said soybean variety CL1460155 has been deposited under ATCC Accession Number PTA-123841.
US Pat. No. 10,188,071

SOYBEAN CULTIVAR CL1460258

Syngenta Participations A...

1. A plant, a plant part, or a seed of soybean variety CL1460258, wherein a representative sample of seed of said soybean variety CL1460258 has been deposited under ATCC Accession Number PTA-123842.
US Pat. No. 10,190,122

INHIBITORY OLIGONUCLEOTIDE AND USE THEREOF

SBI Biotech Co., Ltd., T...


US Pat. No. 10,189,610

STERILIZABLE PVC-FREE CLOSURES

ACTEGA DS GMBH, Bremen (...

1. A vessel cap made of metal or plastic for a vessel for receiving foods or beverages, comprising a seal insert made of a seal material which comprises at least three different polymers mixed with further substances,wherein the seal material comprises no polyvinyl chloride (PVC),
wherein the seal material is substantially free from components that are liquid at application temperature,
wherein the seal material has a Shore A hardness between 40 and 95,
wherein the seal material comprises at least three different polymers, wherein the first polymer is a propylene polymer and/or propylene copolymer, the second polymer is a thermoplastic elastomer, and the third polymer is a polyolefin elastomer,
wherein the seal material is composed such that the seal insert withstands a sterilization at temperatures of above 100° C. and up to 132° C.,
and wherein the seal material, in a dynamic mechanical thermal analysis (DMTA), demonstrates a heating curve for the phase angle tan (delta) the inflection point of which lies above the required sterilization temperature.
US Pat. No. 10,188,073

SOYBEAN VARIETY 5PEGE77

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PEGE77, representative seed of the variety having been deposited under ATCC Accession Number PTA-125526.
US Pat. No. 10,190,138

METHODS USING SHORT CHAIN PERACIDS TO REPLACE ANTIBIOTICS FOR CONTROLLING FERMENTATION PROCESS INFECTION

ECOLAB USA INC., Saint P...

1. A method for replacing antibiotics in fermentation processes comprising:replacing an antibiotic used in a fermentation process to reduce and/or eliminate Lactobacillus and/or Acetobacter species with a peracid composition for application to a fermentation system; and
introducing the peracid composition to a mash source, wherein the peracid composition comprises from about 0.0005 wt-% to about 5 wt-% peroxyformic acid, from about 1 wt-% to about 10 wt-% formic acid, from about 5 wt-% to about 97 wt-% water, from about 0 wt-% to about 20 wt-% anionic surfactant, from about 0 wt-% to about 10 wt-% oxidizing agent; about 0 wt-% to about 35 wt-% inorganic acid, and from about 0 wt-% to about 5 wt-% sequestrant, and wherein the peracid composition does not interfere with yeast fermentation in a fermentation process.
US Pat. No. 10,190,140

INCREASED PRODUCTION OF TERPENES AND TERPENOIDS

EVOLVA SA, Reinach (CH)

1. A method for producing a terpene or a terpenoid in a recombinant host cell, comprising culturing the recombinant host cell under conditions wherein the terpene or terpenoid is produced in the recombinant host cell, wherein the recombinant host cell is genetically engineered to produce reduced expression of an endogenous farnesyl diphosphate (FPP) synthase, an endogenous geranyl diphosphate (GPP) synthase or an endogenous enzyme having both FPP synthase and GPP synthase activity compared to a non-engineered host cell;wherein reduced expression is produced in the recombinant host cell by:
(a) introducing into the recombinant host cell a heterologous genetic construct encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to an exogenous weak promoter, wherein the weak promoter is KEX2, PGK-1, GPD1, ADH1, ADH2, PYK1, TPi1, PDC1, TEF1, TEF2, FBA1, GAL1-10, CUP1, MET2, MET14, MET25, CYC1, GAL1-S, GAL1-L, TEF1, CAG, CMV, human UbiC, RSV, EF-1alpha, SV40, Mt1, Tet-On, Tet-Off, Mo-MLV-LTR, Mx1, progesterone, RU486 or Rapamycin-inducible promoter;
(b) introducing into the recombinant host cell a heterologous genetic construct encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to a messenger RNA destabilizing motif, comprising a M1 motif of SEQ ID NO:28 and/or a M24 motif of SEQ ID NO:29; or
(c) introducing into the recombinant host cell a recombinant genetic construct, the construct comprising a gene encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to an endogenous promoter, wherein between the endogenous promoter and the gene encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity is a heterologous insert sequence having the formula:
-X1-X2-X3-X4-X5-;
wherein X2 comprises at least 4 consecutive nucleotides being complementary to, and forming a hairpin secondary structure element with at least 4 consecutive nucleotides of X4;
wherein X3 either comprises zero nucleotides or one or more unpaired nucleotides forming a hairpin loop between X2 and X4;
wherein X4 comprises at least 4 consecutive nucleotides being complementary to, and forming a hairpin secondary structure element with at least 4 consecutive nucleotides of X2; and
wherein X1 and X5 comprise zero, one or more nucleotides
wherein the recombinant host cell further comprises one or more recombinant expression constructs encoding heterologous enzymes for producing said terpene or terpenoid; and
wherein the recombinant host cell further comprises a recombinant expression construct encoding a truncated version of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGR), comprising the catalytically active carboxyl terminal portion thereof, comprising a region from amino acid 619 to amino acid 1025 of SEQ ID NO:8 and having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:8.
US Pat. No. 10,189,897

PROTEIN PURIFICATION

UCB PHARMA, S.A., Brusse...

1. A process for the purification of an antibody fragment comprising:a) a first chromatography step to capture the antibody fragment wherein a periplasmic cell extract containing bacterial host cell protein in an amount of about 200 ?g/ml to 10,000 ?g/ml and an antibody fragment at a concentration of at least 1.5 g/L is subjected to cation exchange chromatography and subsequently eluted to produce a first eluate containing the antibody fragment; and
b) a second chromatography step wherein the first eluate is subjected to anion exchange chromatography to capture impurities and produce a flow through containing the antibody fragment.
US Pat. No. 10,190,154

REDUCED GRAPHENE OXIDE-BASED BIOSENSORS

McMaster University, Ham...

1. A biosensor comprising:a) reduced graphene oxide (rGO); and
b) a nucleic acid probe absorbed on the rGO, the nucleic acid probe comprising an RCA primer sequence linked to a recognition moiety for an analyte.
US Pat. No. 10,188,620

TREATMENT FOR NAFLD AND NASH

CymaBay Therapeutics, Inc...

1. A method for treating a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject having metabolic syndrome, comprising administering a therapeutically effective amount of seladelpar or a salt thereof to the subject.
US Pat. No. 10,188,111

PHARMACEUTICALLY ACCEPTABLE COMPOSITION COMPRISING DILUTE SODIUM HYPOCHLORITE SOLUTION

Hypo-Stream Limited, Mel...

1. A method of treating infection, preventing infection or aiding healing in a mammal comprising administering to said mammal an effective amount of a composition comprising dilute stabilized sodium hypochlorite solution and a dye to show that the dilute stabilized sodium hypochlorite solution is fresh and active by means of a color change within a period of one hour after said dilute stabilized sodium hypochlorite solution is prepared, wherein said dye selected from the group consisting of azafloxin, basic blue (nil blue sulphate), bismarck brown, basic red (rhodamine 6G), bengal red, brilliant crysyl blue, eosin, fluorescein, gentian violet, indocyanine green, janus green, methylene green, methylene blue, neutral red, trypan blue, and trypan red.
US Pat. No. 10,188,624

ENTERIC SOFT CAPSULES COMPRISING POLYUNSATURATED FATTY ACIDS

Patheon Softgels Inc., H...

1. A method for treating or reducing symptoms of a cardiovascular-related disease comprising administering to a subject in need thereof an oral pharmaceutical dosage form comprising an enteric soft capsule shell comprising:gelatin and an enteric polymer;
wherein a weight ratio of enteric polymer to gelatin is 1:2.6; and
the shell encapsulates a fill comprising at least 70% by weight eicosapentaenoic free fatty acid (EPA), wherein upon administration, the enteric soft capsule reduces onset or ameliorates symptoms of gastrointestinal side effects comprising one or more of eructation, abdominal discomfort, nausea, diarrhea or fishy odor.
US Pat. No. 10,189,908

CHIMERIC ANTIGEN RECEPTORS RECOGNIZING CANCER-SPECIFIC TN GLYCOPEPTIDE VARIANTS

THE UNIVERSITY OF CHICAGO...

1. A cancer-specific Tn glycopeptide binding partner that binds a cancer-specific Tn glycopeptide, wherein the binding partner comprises the antibody heavy chain variable fragment (VH) of SEQ ID NO:19 or a humanized derivative thereof, and the antibody light chain variable fragment (VL) of SEQ ID NO:20 or a humanized derivative thereof.
US Pat. No. 10,190,166

METHODS FOR IDENTIFYING DENDRITIC CELL SUBSETS, FOR DETERMINING IF A PATIENT IS DEVELOPING A REGULATORY OR AN EFFECTOR IMMUNE RESPONSE, AND FOR DETERMINING RESPONSE TO IMMUNOTHERAPY

STALLERGENES, Antony (FR...

1. A method for treating a patient suffering from allergy to an allergen and undergoing allergen immunotherapy, which method comprises:a) administering an effective amount of an allergen immunotherapy to a patient suffering from allergy to said allergen;
b) determining the level of expression, by dendritic cells, of at least STAB1, or an mRNA thereof, in a biological sample from the patient treated with allergen immunotherapy, said biological sample containing dendritic cells;
c) comparing said level of expression with that of a control and
d) based on the comparison with the control, identifying if the immune response developed by the patient is oriented either towards a tolerogenic dendritic cell response or towards an effector dendritic cell response, wherein the control either consists of (i) immature dendritic cells which have not been polarized towards tolerogenic or effector subsets, or where appropriate consists of (ii) a biological sample from the patient obtained before said patient undergoes allergen immunotherapy, said biological sample containing dendritic cells, and wherein step d) is as follows:
identifying that the patient is developing an immune response oriented towards a tolerogenic dendritic cell response when the level of expression, by dendritic cells, of at least STAB1, or an mRNA thereof, is higher than that of the control, and then proceeding with administering further rounds of the same allergen immunotherapy to the patient; and/or
identifying that the patient is developing an immune response oriented towards an effector dendritic cell response when the level of expression, by dendritic cells, of at least STAB1, or an mRNA thereof, is lower than that of the control, and then stopping the allergen immunotherapy to the patient.
US Pat. No. 10,190,169

BIOMARKER IDENTIFICATION

ImmuneXpress Pty Ltd, Bo...

1. A method for treating or inhibiting the development of infection-negative systemic inflammatory response syndrome (inSIRS) or infection-positive systemic inflammatory response syndrome (ipSIRS) in a subject, the method comprising:(1) providing a reference inflammatory response syndrome (IRS) biomarker profile that correlates presence of inSIRS with a first level of a PLAC8 expression product in a reference peripheral blood sample, and that correlates presence of ipSIRS with a second level of the PLAC8 expression product the reference peripheral blood sample, wherein the PLAC8 expression product is an IRS biomarker;
(2) obtaining a sample IRS biomarker profile that evaluates the level of the PLAC8 expression product in a peripheral blood sample taken from the subject;
(3) determining an increased likelihood of the presence of inSIRS or the presence of ipSIRS in the subject based on whether the sample IRS biomarker profile comprises the first level or the second level of the PLAC8 expression product; and
(4) administering to the subject an effective amount of an anti-inflammatory or anti-pyretic agent if the subject is determined to have an increased likelihood of having inSIRS, or administering to the subject an effective amount of an antibiotic agent if the subject is determined to have an increased likelihood of having ipSIRS.
US Pat. No. 10,188,632

OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS

Allergan Holdings Unlimit...

1. A solid pharmaceutical dosage formulation comprising about 20 mg/dose to about 200 mg/dose of 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, about 60-80% by weight of silicified microcrystalline cellulose, about 0.55-0.95% by weight of colloidal silicon dioxide, about 3-7% by weight of crospovidone, about 5-15% mannitol, and about 0.55-0.95% by weight of magnesium stearate,wherein extraction of the formulation with water or saline at 25° C. for up to 12 hours produces a concentration of 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid of less than or approximately 4 mg/ml.
US Pat. No. 10,188,633

IDENTIFICATION OF SMALL MOLECULES THAT FACILITATE THERAPEUTIC EXON SKIPPING

THE REGENTS OF THE UNIVER...

1. A method for enhancing exon skipping in an mRNA of interest, comprising contacting the mRNA with an antisense oligonucleotide that is specific for a splicing sequence in the mRNA and an effective amount of dantrolene, Ryanodine, or RyCal S107, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof.
US Pat. No. 10,189,918

CURABLE FLUOROCOPOLYMER FORMED FROM TETRAFLUOROPROPENE

HONEYWELL INTERNATIONAL I...

1. A copolymer composition comprising:(a) from 45 mol % to 55 mol % of a polymerized monomers of 1,3,3,3-tetrafluoropropene;
(b) from 25 mol % to 45 mol % of polymerized monomers of vinyl esters and vinyl ethers; and
(c) from 5 mol % to 20 mol % of polymerized monomers of hydroxyl group-containing vinyl ether(s).
US Pat. No. 10,190,174

ULCERATIVE COLITIS (UC)-ASSOCIATED COLORECTAL NEOPLASIA MARKERS

Baylor Research Institute...

1. A method for determining increased methylation levels in genes from a sample from a patient with ulcerative colitis comprising measuring in the sample increased methylation levels for genes encoding miR-1 and miR-9 compared to a control or reference methylation level for the genes.
US Pat. No. 10,190,176

PRIMERS, PROBES, AND METHODS FOR MYCOBACTERIUM TUBERCULOSIS SPECIFIC DIAGNOSIS

BOSTON MEDICAL CENTER COR...

1. At least one synthetic oligonucleotide that hybridizes to the Mycobacterium tuberculosis ponA gene, wherein the at least one synthetic oligonucleotide has a set of features selected from:A) a calculated binding value in the range of 60 to 74 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 23 to 27 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 1; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 1 except for the presence of one single point mutation as compared with SEQ ID NO: 1; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 1 except for the presence of two point mutations as compared with SEQ ID NO: 1; or 4) is complementary to any one of 1) to 3);
B) a calculated binding value in the range of 52 to 66 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 21 to 24 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 4; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 4 except for the presence of one single point mutation as compared with SEQ ID NO: 4; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 4 except for the presence of two point mutations as compared with SEQ ID NO: 4; or 4) is complementary to any one of 1) to 3);
C) a calculated binding value in the range of 52 to 66 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 21 to 24 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 5; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 5 except for the presence of one single point mutation as compared with SEQ ID NO: 5; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 5 except for the presence of two point mutations as compared with SEQ ID NO: 5; or 4) is complementary to any one of 1) to 3);
D) a calculated binding value in the range of 51 to 65 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 21 to 24 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 8; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 8 except for the presence of one single point mutation as compared with SEQ ID NO: 8; or 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 8except for the presence of two point mutations as compared with SEQ ID NO: 8; or 4) is complementary to any one of 1) to 3);
E) a calculated binding value in the range of 51 to 65 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 21 to 24 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 7; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 7 except for the presence of one single point mutation as compared with SEQ ID NO: 7; or 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 7 except for the presence of two point mutations as compared with SEQ ID NO: 7; or 4) is complementary to any one of 1) to 3);
F) a calculated binding value in the range of 48 to 62 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 18 to 21 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 10; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 10except for the presence of one single point mutation as compared with SEQ ID NO: 10 ; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 10 except for the presence of two point mutations as compared with SEQ ID NO: 10; or 4) is complementary to any one of 1) to 3);
G) a calculated binding value in the range of 48 to 62 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 18 to 21 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 34 ; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 34 except for the presence of one single point mutation as compared with SEQ ID NO: 34; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 34 except for the presence of two point mutations as compared with SEQ ID NO: 34; or 4) is complementary to any one of 1) to 3);
H) a calculated binding value in the range of 55 to 69 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 23 to 26 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 21; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 21 except for the presence of one single point mutation as compared with SEQ ID NO: 21; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 21 except for the presence of two point mutations as compared with SEQ ID NO: 21; or 4) is complementary to any one of 1) to 3);
I) a calculated binding value in the range of 48 to 62 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 20 to 23 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 24; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 24 except for the presence of one single point mutation as compared with SEQ ID NO: 24; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 24 except for the presence of two point mutations as compared with SEQ ID NO: 24; or 4) is complementary to any one of 1) to 3);
J) a calculated binding value in the range of 52 to 66 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 21 to 24 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 25; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 25 except for the presence of one single point mutation as compared with SEQ ID NO: 25; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 25 except for the presence of two point mutations as compared with SEQ ID NO: 25; or 4) is complementary to any one of 1) to 3);
K) a calculated binding value in the range of 52 to 66 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 21 to 24 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 38; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 38 except for the presence of one single point mutation as compared with SEQ ID NO: 38; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 38 except for the presence of two point mutations as compared with SEQ ID NO: 38; or 4) is complementary to any one of 1) to 3); and
L) a calculated binding value in the range of 52 to 66 inclusive, wherein the nucleobase sequence of said synthetic oligonucleotide: (i) is selected to be from 21 to 24 nucleobase subunits in length; and (ii) possesses a nucleobase sequence that: 1) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 39; 2) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 39 except for the presence of one single point mutation as compared with SEQ ID NO: 39; 3) is identical in nucleobase sequence to a contiguous subsection of SEQ ID NO: 39 except for the presence of two point mutations as compared with SEQ ID NO: 39; or 4) is complementary to any one of 1) to 3).
US Pat. No. 10,190,177

MULTIPLEX ASSAY FOR DETECTION OF BACTERIAL SPECIES IN BIOLOGICAL SAMPLES

The Curators of the Unive...

1. A method for detection of at least one bacterial species in a biological sample comprising real-time PCR amplification, said method comprising:(i) enriching the bacterial concentration of the biological sample to result in an enriched biological sample;
(ii) isolating DNA from said enriched biological sample to produce an isolated DNA sample; and
(iii) detecting a sequence from said at least one bacterial species in said isolated DNA sample via real-time PCR, wherein said real-time PCR comprises:
(a) an internal amplification control comprising at least 90% identity to the internal amplification control set forth in SEQ ID NO:23 and more than one primer pair, wherein each primer of the primer pairs comprises at least 90% sequence identity to a primer set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 or SEQ ID NO:22;
(b) an internal amplification control comprising at least 90% identity to the internal amplification control set forth in SEQ ID NO:31 and more than one primer pair, wherein each primer of the primer pairs comprises at least 90% sequence identity to a primer set forth in SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:30;
(c) an internal amplification control comprising at least 90% identity to the internal amplification control set forth in SEQ ID NO:42 and more than one primer pair, wherein each primer of the primer pairs comprises at least 90% sequence identity to a primer set forth in SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40 or SEQ ID NO:41; or
(d) an internal amplification control comprising at least 90% identity to the internal amplification control set forth in SEQ ID NO:53 and more than one primer pair, wherein each primer of the primer pairs comprises at least 90% sequence identity to a primer set forth in SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51 or SEQ ID NO:52.
US Pat. No. 10,188,640

PHOSPHODIESESTERASE 4 INHIBITORS FOR THE TREATMENT OF A COGNITIVE DEFICIT

Cold Spring Harbor Labora...

1. A method comprising: (a) providing cognitive training to an animal in need of treatment of a cognitive deficit associated with Parkinson's Disease under conditions sufficient to produce an improvement in performance by said animal of a cognitive function whose deficit is associated with the Parkinson's Disease; (b) administering to the animal in conjunction with the cognitive training an inhibitor of phosphodiesterase 1; and (c) repeating steps (a) and (b) one or more times, wherein administration of the inhibitor of phosphodiesterase 1 to the animal in conjunction with the cognitive training results in increased improvement in performance relative to the improvement in performance produced by cognitive training alone.
US Pat. No. 10,190,178

COMPOSITIONS AND METHODS FOR DETECTING MECC-CONTAINING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

Roche Molecular Systems, ...

1. A kit for detecting a nucleic acid of mecC-containing methicillin-resistant Staphylococcus aureus (mecC-MRSA) comprising:a first oligonucleotide consisting of a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 6, and 8;
a second oligonucleotide configured to hybridize to a portion of an orfX gene, consisting of SEQ ID NO: 9; and
a detectably labeled third oligonucleotide configured to hybridize to an amplicon generated by the first oligonucleotide and the second oligonucleotide, consisting of SEQ ID NO: 10, or a complement thereof.

US Pat. No. 10,194,523

CIRCUIT ASSEMBLY, ELECTRICAL JUNCTION BOX, AND MANUFACTURING METHOD FOR CIRCUIT ASSEMBLY

AutoNetworks Technologies...

1. A circuit assembly comprising:a circuit board having an insulating board and a plurality of busbars that are bonded to one side of the insulating board;
an insulating layer that is printed to the plurality of busbars so as to couple adjacent ones of the plurality of busbars to each other;
a heat dissipation member on which the insulating layer is placed and which is configured to dissipate heat conducted from the insulating layer; and
a fixing member that is configured to fix the circuit board and the heat dissipation member to each other in a state in which the insulating layer is sandwiched between the heat dissipation member and the plurality of busbars,
a plurality of low-heat generating components and a plurality of high-heat generating components that generate more heat than the plurality of low-heat generating components are mounted on the circuit board, and
a heat insulating groove is formed in the circuit board at a location between the plurality of low-heat generating components and the plurality of high-heat generating components, the heat insulating groove passing through the circuit board and the insulating layer, and
a heat insulating recess that is continuous with the heat insulating groove is formed in the heat dissipation member.

US Pat. No. 10,194,505

AUDIO BUS LIGHTING CONTROL

Harman International Indu...

1. A method for lighting control by an audio bus lighting control device, the method comprising:receiving, by a lighting control device, audio bus data generated by a source in a vehicle, wherein receiving the audio bus data includes receiving at least one channel of an audio signal of the audio bus;
generating, by a controller of the lighting control device, a lighting control signal for at least one lighting element of the vehicle based on the audio bus data; and
controlling, by a switching unit of the lighting control device, operation of the at least one lighting element of the vehicle based on the lighting control signal.